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TARGETING THE GLUCOSE METABOLISM OF MYELOID-
DERVIED SUPPRESSOR CELLS (MDSCs) TO STIMULATE 
CANCER IMMUNITY 
Jaspreet Grewal 
April 20, 2017 
 
Myeloid derived suppressor cells (MDSCs) are a heterogeneous group of 
immature myeloid cells that are significantly increased in cancer patients and 
correlate with higher stage and poor prognosis (1-4). MDSCs negatively 
modulate anti-tumor immunity, suppress T cell activity, promote angiogenesis 
and increase the risk of metastasis (1). In this study, we report that monocytic-
MDSCs (M-MDSCs) but polymorphonuclear-MDSCs (PMN-MDSCs) over-
express 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatases 3 (PFKFB3), 
an important regulator of glycolysis. Furthermore in the melanoma model, M-
MDSCs but not PMN-MDSCs suppressed T cell function which correlated with 
PFKFB3 over-expression and increased rate of glycolysis. PFKFB3 inhibition 
with the first-in-class small molecule inhibitor, PFK-158 reversed M-MDSC 
mediated T cell suppression and decreased the expression of arginase 1 and 
inducible nitric oxide synthase (iNOS) both in vitro and in vivo. In addition, both in 
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B16-F10 tumor-bearing mice and patients enrolled in Phase 1 clinical trial, 
PFKFB3 inhibition resulted in decrease in M-MDSC frequency and increase in 
effector T cell populations. In this first-of-a-kind study, we present strong 
evidence for targeting metabolic profile of M-MDSCs to modulate their immune 
suppressive phenotype. This study provides the basis to study PFK-158 as an 
immunomodulatory agent in combination with immune checkpoint blockade 
therapies to improve T cell activity and anti-tumor responses.
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1.1 Historical background 
About 35 years ago, Strober et al identified a population of myeloid cells 
with T-cell suppressive functions affecting alloreactive immune responses in 
allogeneic bone marrow chimera experiments (1, 5). Because of the lack of 
common phenotypic markers, these cells were originally called the “natural 
suppressor (NS)” cells (5). Initially, these cells were thought to appear only 
transiently during certain phases of life such as in the placenta during pregnancy, 
fetus and during maturation of lymphoid tissues in neonates (5). However, later 
these cells were also identified following immune system manipulation such as 
following total body irradiation (TBI) or chemotherapy, in chronic inflammatory 
states, graft-versus-host disease (GVHD) and cancer (5). Due to technical 
difficulties associated with the isolation and disagreements in the scientific 
community regarding phenotypic characterization, these cells were defined on琀
the basis of their suppressive function
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First evidence for the involvement of NS cells in lowering immune 
surveillance and in promoting cancers came in 1995. It was noticed that following 
the administration of an antibody directed against the glutathione reductase 1 
(GR1 or GSR) antigen, which recognizes cross-reacting molecules of lymphocyte 
antigen 6 complex locus C and G or Ly6C and Ly6G, to immunocompetent mice 
reduced the growth of UV light-induced tumor (5). It was initially thought that the 
GR1 antibody resulted in the elimination of granulocytes; however, subsequent 
studies showed that the GR1pos cells were mainly CD11bpos (integrin‑αM) 
polymorphonuclear and mononuclear cells at different stages of maturation along 
the myelomonocytic differentiation lineage (5, 6). 
Subsequently, observations were made during therapeutic anticancer 
vaccine research with powerful immunogens which revealed dysfunction of 
CD8pos cytotoxic T-lymphocytes (CTLs) in immunocompetent hosts (7). This 
observation was attributed to accumulation of splenic CD11bposGR1pos cells (7). 
Following elimination of this cell population, CTL function was restored both in 
vitro and in vivo (7). In 2001, it was reported that the decrease in the dendritic 
cells (DCs) in the peripheral blood of cancer patients correlated with the 
appearance of immature cells lacking markers of mature lymphoid and myeloid 
cells (7). These immature cells capable of suppressing T-cell responses were 
called “immature myeloid cells” (ImCs) and were characterized by the absence of 
lineage markers such as CD3, CD19 and CD57 (7). They were positive for CD13, 
CD33 and lacked the expression for HLA-DR and CD15. After few years, the 
term “ImCs” was dropped and it was proposed that these cells be called “Myeloid 
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Suppressor Cells” (MSC) (1). A myeloid cell suppressive population 
characterized as CD14posHLA-DRlow/neg was identified for the first time in 
melanoma patients treated with an anti-cancer vaccine containing GM-CSF as an 
adjuvant (7). Finally in 2007, the term MDSC was formally introduced to 
characterize these immature myeloid cells in both mice and humans (1, 8). 
1.2 Phenotype of myeloid derived suppressor cells (MDSCs) 
MDSCs are a heterogeneous group of bone marrow derived immature 
myeloid cells at different stages of differentiation which are greatly expanded in 
cancers, inflammation, trauma and infection, and suppress both innate and 
adaptive immune responses (Fig. 1) (1, 2, 4, 7-35). This population of cells 
includes immature monocytes, granulocytes and other myeloid progenitors (9, 
11-13, 17, 25, 26, 28, 36). MDSCs are characterized by morphological, 
phenotypic and functional heterogeneity which essentially demonstrates the 
plasticity of this immune suppressive cell population (35). This further outlines 
how different tumors, infectious agents or inflammatory states can result in 
similar biological effects on myeloid progenitors despite the differences in the 
factors that they produce (8). This heterogeneity over the years created 
tremendous amount of ambiguity and confusion in developing a standard 
definition and other biological characteristics of MDSCs. To overcome this 
limitation, standard definitions characterizing the phenotypical and functional 
characteristics of these cells were published recently (35).  
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Cells with typical MDSC phenotype are present in the bone marrow and in 
the spleens of healthy individuals as well as naïve mice (13, 17, 24, 37). Under 
normal conditions, these cells make up about 20-40% of the bone marrow and 
about 2-4% of all splenocytes (9, 11, 13, 17, 24, 36, 37). However, these cells 
are not suppressive and largely represent ImCs (7, 13, 15, 22, 37). Under normal 
conditions, these ImCs migrate to the peripheral lymphoid organs and 
differentiate into macrophages, DCs, and granulocytes/neutrophils (1, 17, 35, 
37). In cancer, hematopoietic differentiation pathway is altered and maturation of 
these cells into normal myeloid cells is blocked. These cells under the influence 
of tumor-derived soluble factors (TDSFs) become activated, expand 
exponentially (>20% of all splenocytes in some tumor models) and accumulate in 
peripheral blood, lymph nodes, spleen, tumors, and immune-activated tissues 
and develop in to immune suppressive MDSCs (1, 11, 12, 22, 35, 38). 
Interestingly, acute bacterial infection or stress does not necessarily result in the 
generation of MDSCs. They accumulate only during chronic infection, 






Figure 1. Normal vs. abnormal differentiation of immature myeloid cells to 
terminally differentiated cells and MDSCs (25). 
In mice, MDSCs are generally defined as CD11b and GR1 positive (6, 8-
16, 19-22, 24, 25, 27, 28, 30, 35-37, 39-41). Further classification of murine 
MDSCs to monocytic (M-) and granulocytic or polymorphonuclear (PMN- or G-) 
MDSCs is based on graded measurements of GR1 expression or by using two 
different GR1 epitopes (8, 12, 20, 35). To differentiate MDSCs from steady state 
granulocytes, it is now proposed to use the term PMN-MDSCs as opposed to G-
MDSCs (35). Murine M-MDSCs are SSClowCD11bposLy6ChighLy6Gneg CD49dpos 
(or GR1low) and G- or PMN-MDSCs are SSChighCD11bposLy6ClowLy6Gpos 
CD49dneg (or GR1high) (1, 5-22, 24-26, 30, 33-38, 41-46). Both subsets express 
IL-4Rα (CD124); however, expression is higher in GR1low compared to GR1high 
subset (7, 42, 47, 48). Murine M-MDSCs also express chemokine receptor 2 
(CCR2) and low levels of F4/80, and PMN-MDSCs express CD244 (7, 42). 
Macrophage – colony stimulating factor receptor (M-CSFR or CD115) is 
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expressed by both subsets (7). On May-Grünwald-Giemsa staining, PMN-
MDSCs are morphologically similar to neutrophils and M-MDSCs are similar to 
monocytes (5, 7, 47, 49).   
Human M-MDSCs are generally defined as 
CD11bposCD14posCD15negCD33posHLA-DRlow/neg and PMN-MDSCs as 
CD11bposCD14negCD15posCD33dimCD66bpos (1, 4-12, 15-19, 22, 24-26, 28, 30, 
34, 35, 37, 44, 45, 49, 50). Another population of more immature progenitors 
lacking lineage specific antigens (Linneg) such as CD3, CD14, CD15, CD19, 
CD20, CD40, CD56, CD57, CD80 and CD83 but positive for CD33 has been 
recently classified as  “early-stage MDSC (eMDSC)” (1, 7, 17, 19, 35). Both 
mature monocytes and granulocytes express HLA-DR. Interleukin – receptor 
alpha (IL-4Rα or CD124), IL-13, vascular endothelial growth factor receptor 
(VEGFR) and macrophage – colony stimulating factor receptor (M-CSFR or 
CD115) are other markers that define immune suppressive MDSCs in humans 
(1, 6, 13, 15, 19-21, 37).  
1.3 Functional characteristics of MDSCs 
Tumors and TDSFs not only sustain the accumulation of MDSCs but also 
determine their functional differentiation leading to their heterogeneity in different 
cancers and tumor models. This makes it important to not only determine the 
presence of all MDSC subsets in each cancer patient, but also which MDSC 
subsets have clinical relevance in a particular tumor environment/model (21).  
7 
 
Both MDSC subsets undergo substantial expansion in the peripheral 
blood, lymphoid organs and spleens of tumor bearing animals and cancer 
patients. PMN-MDSCs expand in much greater numbers accounting for 70–80% 
of the MDSC population in a tumor bearing host, whereas M-MDSCs account for 
20–30% of MDSCs (Fig. 2) (5, 7, 8, 13, 21, 24, 25). M-MDSC, however, is the 
dominant subset at the tumor site (21, 51). This may be secondary to the 
chemokines produced by the tumor cells that support preferential migration of M-
MDSCs to the tumor site or alternatively, the TME may not support PMN-MDSC 
survival because of hypoxia, low pH, and accumulation of metabolic products 
(Fig. 2) (21, 51). Regardless, M-MDSCs are more suppressive on a per cell 
basis compared with PMN-MDSCs in most tumor models and cancer patients (5, 
8, 36, 42, 47). Interestingly, MDSC frequencies start to increase early during 
tumor development, but only MDSCs from mice with established tumors 




Figure 2. Expansion and migration of MDSCs from the bone marrow to 
peripheral lymphoid organs and tumor (51).  
MDSCs potently suppress both innate and adaptive immunity through 
inhibition of T cell activation, disruption of naive T-cell homing to lymph nodes, 
suppression of NK cell cytotoxicity, expansion of Tregs cells and arrest of DC 
maturation (1, 15-18, 20, 32, 45, 52). In addition, MDSCs protect tumors from the 
effects of chemotherapy and radiotherapy, drive tumor growth by promoting 
cancer stemness, promote angiogenesis through upregulation of vascular 
endothelial growth factor (VEGF), beta – fibroblast growth factor (bFGF), VEGF 
analogue Bv8, stroma deposition and epithelial-to-mesenchymal transition 
(EMT), and facilitate tumor cell motility and metastasis through expression of  
matrix metalloprotease (MMP9) (6, 8, 11, 12, 17, 25, 33, 53).  
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MDSC employ several mechanisms to inhibit T cell activity which includes 
arginine depletion through expression of the enzyme arginase 1 (Arg1), 
production of reactive oxygen species (ROS) and reactive nitrogen species 
(RNS), expression of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) 
production, up-regulation of cyclooxigenase-2 (COX-2) and prostaglandin E2 
(PGE2) production, induction of Tregs, expression of transforming growth factor 
– β (TGF-β) and interleukin – 10 (IL-10), sequestration of other amino acids such 
as cysteine, cystine and phenylalanine, depletion of tryptophan through 
expression of indolamine 2, 3-dioxygenase (IDO) and down-regulation of L-
selectin expression on T cells (1, 9, 10, 13, 15-17, 24-26, 31, 36, 39, 45, 46, 51). 
Functional differences between MDSC subsets pertain to their mechanism 
of T cell suppression. PMN-MDSCs mainly suppress T cell function through 
production of high levels of ROS, expression of Arg1 and myeloperoxidase 
(MPO) whereas M-MDSCs suppress T cell function by depleting arginine through 
expression of Arg1, and production of NO and RNS through expression of iNOS 




Figure 3. Markers of suppression of polymorphonuclear- and monocytic-
MDSCs (25). 
Similarly, MDSCs isolated from peripheral lymphoid organs and tumors 
have profound functional differences despite similar phenotype and morphology. 
Tumor MDSCs suppress both antigen-specific and nonspecific T cell activity (8, 
11, 25). However, MDSCs isolated from peripheral lymphoid organs fail to 
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suppress antigen-nonspecific T cell function but mediate antigen-specific T-cell 
tolerance by processing and presenting tumor associated antigens (TAAs) to T 
cells in the context of major histocompatibility complex class – I (MHC-1) (8, 9, 
11, 25). This observation is supported by the fact that despite the presence of a 
large number of MDSCs in the spleens and lymph nodes of tumor-bearing mice 
and in the peripheral blood of cancer patients with advanced disease, T cells 
mostly retain the ability to respond to different tumor-nonspecific stimuli including 
viruses, lectins, costimulatory molecules, IL-2, and stimulation with CD3- and 
CD28-specific antibodies (11). 
Molecular mechanisms behind MDSC recruitment, expansion, and 
activation are still not clear. However, a “two-signal” model has been proposed 
(8, 18, 34, 51). First step is promoted by chronic inflammation resulting in 
accumulation of immature cells and involves factors such as granulocyte colony 
stimulating factor (G-CSF), macrophage-colony stimulating factor (M-CSF), GM-
CSF, C-X-C motif chemokine ligand 5 (CXCL5), CXCL12, C-C motif chemokine 
ligand 2 (CCL2), cyclooxygenase-2 (COX-2) and PGE2, VEGF, IL-1β, IL-4, IL-6, 
IL-8, IL-10, IL-12, IL-13, IL-17, FMS like tyrosine kinase 3 ligand (FLT3L), 
fibroblast growth factor – 2 (FGF-2), S100A8/A9, stem cell factor (SCF or KIT 
ligand), TGF-β and tumor necrosis factor α (TNFα) (Fig. 4) (1, 5, 6, 12, 13, 15, 
18, 21, 25, 26, 28, 30, 32-34, 38, 39, 42, 47, 51). These signals converge on one 
common pathway – Janus kinase/signal transducers and activators of 
transcription 3 (JAK/STAT3) pathway involved in cell survival, proliferation and 
differentiation (Fig. 4) (9, 12, 20, 21, 46). MDSCs isolated from tumor bearing 
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mice and patients with malignant melanoma have dramatically increased levels 
of phosphorylated STAT3 (pSTAT3) compared to ImCs from naive mice or 
healthy donors (Fig. 4) (8, 9, 15, 21, 25, 30). STAT3 is important for MDSC 
recruitment and suppressive activity through increased levels of Arg1, NADPH-
oxidase 2 (NOX2), iNOS or Nos2, IDO, VEGF, GM-CSF, S100A8/A9, 
cyclooxygenase (COX)-2, IL-1β, IL-6 and IL-10 (Fig. 4) (9, 12, 15, 21, 26, 30, 34, 
39, 46). In addition, STAT3 is responsible for maintaining MDSCs in immature 
state and preventing their differentiation through upregulation of B-cell lymphoma 
XL (BCL-XL), cyclin D1, MYC and survivin (8, 12, 15, 21, 25, 30, 34).  
The second signal is needed for the pathological activation of these cells. 
The factors involved in the second signal are produced mainly by activated T 
cells, tumor stromal cells or are induced by different bacterial and viral products, 
or result from tumor-cell death, and include molecules such as IFN-γ, IL-1β, IL-4, 
IL-13, TGFβ and TLR ligands (51). These factors activate several signaling 
pathways in MDSCs that involve STAT1, STAT6 and nuclear factor-κB (Fig. 4) 
(15, 25, 30, 46, 51). 
Bronte et al have reported that CCAAT/enhancer-binding protein beta 
(C/EBPb) family of transcription factors along with STAT proteins regulate shift 
from normal to aberrant hematopoiesis, allowing differentiation into MDSCs, 
recruitment and activation (Fig. 4) (46). In a separate study, Ostrand-Rosenberg 
et al proposed that MDSC levels in developing tumors are maintained by 
resistance to apoptosis by FasL+ expressing activated T cells which is mediated 




Figure 4. External and internal signals involved in MDSC accumulation, 






1.3.1 Arginine depletion 
Both MDSC subsets – PMN- and M-MDSCs use L-arginine depletion as 
mechanism for their T cell inhibitory activity. M-MDSCs from tumor-bearing mice 
express high levels of Arg1 and this is accompanied by high iNOS activity likely 
through the combined autocrine action of IL-13 and IFN-γ (4, 12, 19, 34, 36). 
Arg1 hydrolyzes the amino acid L-arginine to ornithine and urea, and 
iNOS/NOS2 oxidizes L-arginine to generate NO and citrulline (Fig. 4) (1, 17, 21, 
36, 42, 46). In mice, Arg1 remains cytoplasmic while in humans it is secreted 
from the cell (12, 36). 
L-arginine is essential for T cell replication and proliferation (1). Increased 
Arg1 activity leads to enhanced L-arginine catabolism resulting in depletion of 
this non-essential amino acid from the TME. This depletion results in translational 
blockade of the CD3ζ (CD247) chain and prevents T cells from responding to 
various stimuli (10, 26, 38). Further, lack of L-arginine blocks protein translation 
through the accumulation of empty aminoacyl-t-RNAs. This in turn results in 
activation of general control nonderepressible 2 (GCN2) kinase and 
phosphorylation of the translation initiation factor eukaryotic initiation factor 2 α 
(eIF2α). Phosphorylation of eIF2α increases its affinity for eIF2β which blocks the 
exchange of GDP with GTP, thus interfering with protein synthesis. Finally, L-
arginine depletion results in G0–G1 cell cycle arrest through upregulation of cyclin 
D3 and cyclin dependent kinase 4 (cdk4) but not cyclin D1, cyclin D2, and cdk6 
(1, 6, 12, 19, 21, 25, 34, 36). Tumor-infiltrating M-MDSCs further upregulate 
expression of Arg1 which is accompanied by antigen-nonspecific T cell 
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suppression (42). Inhibition of Arg1 restores T-cell function in vitro and induces 
an antitumor response in vivo. Arg1 acts as a tumor-landscaping gene by 
supporting tumor growth and suppressing antitumor immune responses (54). 
In melanoma patients, ARG1 expression has been shown to be a 
dominant mechanism of T cell suppression (19). A recent study had 
demonstrated that the increased numbers of MDSCs in the peripheral blood of 
esophageal, gastric and renal cancer patients correlated with low L-arginine and 
high ornithine levels in plasma, and a profound T-cell dysfunction (4, 12, 36). 
1.3.2 Nitric Oxide (NO) 
Monocytic subset of MDSCs is the predominant producer of NO through 
increased expression of iNOS/NOS2 (42). iNOS is another L-arginine 
catabolizing enzyme which results in the production of NO as a byproduct 
following the conversion of L-arginine to citrulline (Fig. 4).  
High levels of NO produced by M-MDSCs inhibit T cell activity through 
different mechanisms. Similar to Arg1 activity, iNOS expression results in the 
depletion of L-arginine causing down regulation of CD3ζ chain, thus rendering 
the T cells unresponsive (36, 52). NO can result in the nitration of proteins 
involved in interferon receptor signal transduction which reduces responsiveness 
of immune cells to cytokine stimulation (31). In human T cells, NO affects the 
stability of IL-2 mRNA and the release of IL-2. High concentrations of NO can 
inhibit T-cell signaling cascade downstream of the IL-2 receptor in an antigen 
independent manner by blocking the phosphorylation of JAK1, JAK3, STAT5, 
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extracellular signal-regulated kinase (ERK) and protein kinase B (PKB/AKT) 
which are important downstream signaling molecules (6, 34). High levels of NO 
prevent downregulation of L-selectin (CD62L) but cause downregulation of 
homing cell adhesion molecule (CD44) and selectin P ligand (CD162) (34). NO 
negatively regulates intracellular signaling proteins either directly, by S-
nitrosylation of crucial cysteine residues, or indirectly, by activation of soluble 
guanylate cyclase and cyclic-GMP-dependent protein kinase (34). Increased 
production of NO inhibits the expression of MHC class II and induces T-cell 
apoptosis likely mediated by the accumulation of the tumor suppressor protein 
p53, signaling by CD95 (Fas) and TNF receptor family members, or signaling 
through caspase-independent pathways (6, 25, 36).  
1.3.3 Peroxynitrite (PNT) 
Both subsets of MDSC produce increased levels of PNT (ONOO−). PNT is 
a product of interaction between NO and superoxide (O2•–), therefore, increased 
level of either ROS or NO would result in increased PNT (12, 13, 34, 36, 55). 
PNT can also be produced by the combined activity of Arg1 and iNOS. L-arginine 
depletion by Arg1 switches on the reductase domain on iNOS leading to the 
production of superoxide anion and subsequently PNT (6, 34). It is one of the 
most powerful oxidants and is present at sites characterized by accumulation of 
MDSC, inflammatory cells, or ongoing immune reactions (36). 
Increased PNT activity is associated with nitration and nitrosylation of the 
amino acids cysteine, methionine, tryptophan, and importantly tyrosine in 
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different proteins and enzymes, thus changing their biological functions (6, 12, 
25, 34). PNT also causes oxidation of lipids and nucleic acids, and thus affecting 
their normal functions (6, 34). PNT directly inhibits T cell activity through nitration 
of TCRs, thereby reducing their responsiveness to cognate antigen-MHC 
complexes (8, 12, 21, 36). Nitration of the TCR also reduces binding of antigenic 
peptides to MHC molecules on tumor cells. Moreover, PNT can act on α and β 
chains of the lymphocyte TCR, preventing signaling and promoting dissociation 
of the CD3ζ chain from the complex (6). High levels of PNT block T cell migration 
by nitrating T cell–specific chemokines and promote homing of immune-
suppressive subsets other than T cells (6, 8, 12). 
High levels of PNT are directly implicated in tumor progression, via 
modification and inactivation of different proteins (25). Association of high PNT 
levels with tumor progression has been documented in breast, colon, head and 
neck, lung and pancreatic cancers, malignant gliomas, melanoma and 
mesothelioma (36, 55). In breast cancer patients, high tumor PNT levels 
correlated with reduced disease-free survival (DFS) and OS (55). 
1.3.4 Reactive oxygen species (ROS) 
PMN-MDSCs induce T cell suppression mainly through production of high 
levels of ROS. PMN-MDSCs significantly increase the expression of NOX2, 
primarily p47phox and gp91phox catalytic subunits, an enzyme that reduces 
oxygen to superoxide anions using electrons supplied by NADPH (9, 10, 21, 36). 
Another mechanism involved in the generation of ROS involves the combined 
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activity of Arg1 and iNOS. During L-arginine deprivation caused by increased 
Arg1 activity, iNOS utilizes molecular oxygen as the principal substrate to 
produce superoxide anions (21, 36). 
Expression of NOX2 subunits is finely tuned at transcriptional and 
posttranslational level. Cytokines such as IL-3, IL-6, IL-10, TGFβ, TNF-α and 
IFN-γ, growth factors such as platelet derived growth factor (PDGF), GM-CSF 
and VEGF, and transcription factors mainly STAT3 upregulate NOX2 levels, 
whereas specific phosphorylation patterns and subunit availability modulate its 
activity (6, 25). 
Increased levels of ROS are responsible for maintaining the immature 
phenotype of MDSCs and inhibit their differentiation to mature myeloid cells (9). 
ROS results in the loss of T cell receptor (TCR) ζ-chain which is very important 
for transduction of activating signals required for T cell proliferation and cytokine 
secretion (1, 12, 17, 42). Similar to the PNT activity, ROS can cause protein 
oxidation, frequently affecting tyrosine side chains. This impairs the ability of TCR 
to interact with peptide-MHC complexes and prevent appropriate T cell response 
(12). It also causes oxidation of lipids, nucleic acids and proteins which modifies 
their tertiary and quaternary structures and subsequently results in modification 






1.3.5 Regulatory T cells (Tregs) and Th17 cells 
Tregs represent another immune suppressive population that potently 
inhibits T cell and NK cell function in cancer patients and tumor-bearing mice. 
CD4posCD25pos Tregs expressing the transcription factor, forkhead box P3 
(Foxp3) inhibit autoimmune responses and promote tumor growth. Depletion of 
Tregs, thus results in improved antitumor immune responses and delays tumor 
growth (42). MDSCs specifically M-MDSCs promote the induction and 
proliferation of these Tregs, thereby downregulating anti-tumor immune 
responses (12, 25, 52).  
M-MDSCs produce increased levels of CCR5 ligands CCL3, CCL4, and 
CCL5. Because CCR5 is preferentially expressed on Tregs, tumor-infiltrating M-
MDSCs directly attract high numbers of Tregs via CCR5 in vitro. Further in vivo 
studies showed that the intratumoral injection of CCL4 or CCL5 increased tumor-
infiltrating Tregs, and deficiency of CCR5 led to their significant decrease. 
Studies done in CCR5-deficient mice, showed that tumor growth was delayed 
which points to the importance of CCR5 in the control of antitumor immune 
responses (42).  
Because of their ability to suppress T cell activity, accumulation of Tregs 
at the tumor site is associated with poor prognosis (42). It has been shown that in 
hepatocellular carcinoma (HCC), M-MDSCs exert their immunosuppression 
partially through the induction of functional Tregs when co-cultured with 
autologous T cells. The induction of Tregs depended on cell-to-cell contact and 
was abolished when M-MDSCs and T cells were separated (49). Another study 
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showed a significant increase in Tregs in esophageal, gastric and pancreatic 
cancer patients compared with healthy controls. And, there was a positive 
correlation between the increase in MDSC and Treg numbers (4). A direct 
correlation between high levels of Tregs in tumors, and high tumor grade and 
stage and poor prognosis has been demonstrated in different cancers (4, 42). 
Sunitinib, which is multi-tyrosine kinase inhibitor, resulted in significant reduction 
in MDSC numbers in patients with renal cell carcinoma (RCC). And, this 
decrease in MDSC numbers significantly correlated with decrease in Tregs (4).  
Another population of immune regulatory cells induced by MDSCs is the 
Th17 cells. The generation of Th17 cells by MDSCs did not depend on cell-to-cell 
contact but was more dependent on the secretion of various cytokines. It has 
also been shown that the suppressive activity of MDSCs increased following 
incubation with IL-17 through the upregulation of Arg1, IDO, and COX-2. Another 
study showed that MDSCs from tumor-bearing IL-17 knock-out mice were less 
suppressive and expressed lower levels of Arg1, MMP9, and S100A8/A9 
compared with tumor-bearing WT mice (49). These studies suggest that MDSCs 
and Th17 cells likely upregulate each other’s populations through secretion of 
various cytokines such IL-17.  
1.3.6 Programmed death ligand 1/2 (PD-L1/2) 
A recent study has shown that most of ImCs and MDSCs expressed PD-
L1 and CD80 but not PD-L2 (13). No significant differences were noted in the 
percentage of PD-L1 or CD80 positive cells within the populations of ImCs from 
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naïve mice and MDSCs from tumor-bearing mice (13). Further PD-L1 blockade in 
vitro or in vivo did not ameliorate MDSC associated T cell suppression (13). Lack 
of increased expression and no effect of PD-L1 blockade in MDSCs points to the 
fact that these molecules may have no role in MDSC mediated immune 
suppression in cancer (3, 13). 
1.3.7 Indoleamine 2,3 dioxygenase (IDO) 
IDO, an intracellular enzyme is a key regulator of tryptophan 
metabolism/catabolism (7). Tryptophan is essential for  T-cell function and 
immune regulation (7). IDO expression depends on the pSTAT3 (7). L-tryptophan 
starvation inhibits T cell proliferation by activating GCN2 kinase and causing cell 
cycle arrest. Depletion of tryptophan can induce T cell anergy and direct CD4 T-
cell differentiation towards Tregs by Foxp3 upregulation (6). IDO was found to be 
increased in M-MDSCs isolated from both chronic lymphocytic leukemia (CLL) 
patients and patients after allogeneic hematopoietic stem cell transplantation 
(allo-HCT) (7).  
1.3.8 Inhibition of NK cell activity 
MDSCs have also been shown to have potent NK cell inhibitory activity 
(10). M-MDSCs efficiently block NK cell proliferation, cytokine production, and 
cytotoxicity (12). Murine studies have demonstrated an inverse correlation 
between NK cell activation and MDSC frequency (12). NK cell inhibitory activity 
of MDSCs is not mediated by ARG, iNOS, or IDO, but required MDSC-NK cell 
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contact involving the NK cell activating receptor NKp30 (12, 19). Furthermore, 
MDSCs block perforin and NKG2D expression, and IFN-γ production both in vitro 
and in vivo (12). In vitro studies have demonstrated that blockade of NKp30 and 
depletion of MDSCs can reverse MDSC suppressive activity on NK cells (19). 
1.3.9 Cysteine depletion 
MDSCs also deplete cysteine in the TME, another amino acid essential for 
T cell activation, proliferation, and differentiation (1, 28, 42). Cells are able to 
import cystine (an oxidized form of cysteine) from exogenous sources either 
through the cysteine-glutamate (XC) transporter or from the conversion of 
methionine by cystathionase (6). However, T cells lack both and are entirely 
dependent on cysteine in the environment which is normally produced by mature 
DCs and macrophages during antigen presentation (1). During this process, 
antigen presenting cells (APCs) release reduced cysteine in the extracellular 
space through the alanine-serine-cysteine (ASC) transporter which can then be 
taken up by T cells. However, MDSCs express xc-transporter allowing for the 
uptake of cystine but lack ASC transporter to export cysteine and do not express 
cystathionase. This results in sequestration of cysteine in the MDSCs, thereby 






1.3.10 Other mechanisms of T cell suppression 
PGE2 produced by the cancer cells via COX-2 has been shown to be an 
important stimulus for Arg1 expression. COX-2 has also been to shown to be 
overexpressed in MDSCs. Studies have shown that COX-2 inhibitors in vitro and 
in vivo improve anti-tumor T cell immune responses (34). 
MDSC also play an important role in tumor progression and angiogenesis 
through expression of VEGF and MMP9. A recent study has revealed a more 
direct role of MDSC in tumor vascularization. MDSCs when co-injected with 
tumor cells lined the endothelial walls of newly formed tumor vasculature and 
differentiated into cells with endothelial cell characteristics (12). 
M-MDSCs isolated from prostate cancer patients expressed high levels of 
IL-10 while in melanoma patients they expressed high levels of TGF-β (12). TGF-
β expression has direct effect on T cell proliferation. It results in cell cycle arrest 
typically in the G1 phase through the expression of the cell cycle inhibitors 
p27Kip1 and p21Cip1 or by inhibiting IL-2 secretion (6). TGF-β has also been 
shown to inhibit the differentiation of CD4 T cells into Th1 or Th2 cells by 
suppressing the expression of T-bet and GATA-3 respectively (6). TGF-β-
producing MDSCs promote the clonal expansion of antigen-specific natural Treg 
cells and induce the conversion of naïve CD4 T cells into induced Treg cells (6). 
MDSCs also down-regulate the expression of the lymph node homing 
receptor, CD62L on CD4 and CD8 T cells. As consequence, T cells do not 
migrate to lymph nodes where they would otherwise undergo activation (1). 
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1.4 Clinical relevance of increased MDSCs in cancer 
Numerous studies have demonstrated an increase in MDSC population in 
patients with cancer (9, 11, 13, 17). However, significant difference is only 
observed between patients with advanced tumor and healthy donors while 
patients with stage I/II cancers have moderately increased percentage and 
absolute number of circulating MDSCs (13, 22). There is a significant correlation 
between circulating MDSC, and clinical cancer stage and prognosis (2, 10, 12, 
13, 15, 17, 21, 50, 52). Patients with extensive metastatic tumor burden have the 
highest percent and absolute number of MDSCs (10, 13). MDSCs are increased 
in patients with different cancers such as breast, bladder, gastrointestinal, head 
and neck, hepatocellular, non-small cell lung, prostate and thyroid cancers, 
melanoma, multiple myeloma (MM), ovarian carcinoma, RCC, glioblastoma and 




Figure 5. High MDSC count is inversely correlated with overall survival (OS) 
(2-4) 
Studies have shown that if tumor-derived MDSCs were placed in culture 
conditions without TDSFs or injected into tumor-free recipients, they differentiate 
into mature functionally competent macrophages (MΦ) and DCs (24). This is 
consistent with observations that surgical removal of tumors result in elimination 
or decrease in MDSCs (15, 24). Also, these cells express no suppressive activity 
compared to MDSCs from patients with active disease (15). It has also been 
observed that antibody-mediated depletion of MDSCs restores T cell frequency 
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and function (5). In a study of patients with newly diagnosed stage I-IV solid 
cancers, circulating M-MDSCs levels prior to the start of treatment were found to 
correlate both with clinical stage (p <0.0001) and metastatic burden (p <0.01) 
(28). Also, patients with radiographic evidence of disease progression had 
increased levels of circulating MDSCs while the patients who responded to 
treatment had decreased MDSCs (28). 
In melanoma, M-MDSCs (CD14posHLA-DRlow/neg) population is expanded 
in the peripheral blood and is associated with CD4 and CD8 T cell suppression, 
decreased IFN-γ production and decreased OS (2, 10, 15, 26, 39, 50, 52). 
Studies have shown that in patients with malignant melanoma, even at the 
physiologically low MDSC to T cell ratio of 1:4; MDSCs suppressed T cell 
proliferation and IFN-γ production by 40% (15, 17, 26). Recent studies have also 
suggested that increased numbers of pretreatment MDSCs and Tregs, and high 
levels of lactate in patients with advanced melanoma predicts poor response to 
ipilimumab (Yervoy®) (2, 7, 56). 
Studies have reported that the presence of increased number of MDSCs 
predicted poor OS in breast, colon, esophageal, gastric and pancreatic cancer 
patients (Fig. 5) (12, 22). In another study of patients with pancreatic cancer, 
high CD14pos cells to CD8 ratio in the tumor infiltrates correlated with a 
significantly reduced OS (7). In HCC, impaired DC function correlated with the 
presence of CD14posHLA-DRlow/neg M-MDSC cell population (19). 
Different studies have shown the increased presence of both PMN- and 
M-MDSCs in patients with RCC (15, 22). This increase was negatively 
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associated with OS in the retrospective analysis of RCC patients (22). Circulating 
M-MDSCs and Tregs are increased in patients with metastatic prostate cancer 
(mPC) compared to healthy donors and negatively correlates with OS (6, 52). 
Further, M-MDSCs isolated from patients with mPC express significantly high 
levels of iNOS compared with healthy donors (6, 52). 
A recent study reported that the suppressive activity of human MDSCs 
resides in a CD14posS100A9pos inflammatory monocyte or M-MDSC population in 
non-small cell lung cancer (NSCLC) patients (22). Ovarian carcinomas recruit 
CD14pos cells that inhibit T cell proliferation and negatively correlate with OS and 
DFS in both primary and metastatic ovarian cancers (10).  
In MM, CD14posHLA-DRlow/neg M-MDSCs are significantly increased in both 
PB and bone marrow of patients with active disease compared with healthy 
donors (15, 52).  These cells also possess more pronounced inhibitory capacity 
compared to cells with similar phenotype from healthy donors (15, 52). 
Furthermore, studies have demonstrated a bidirectional relationship between 
MDSCs and MM cells and immune effector cells. MDSCs induce MM growth and 
suppress T cell activity. While MM cells induce the development of MDSCs from 
healthy donor peripheral blood mononuclear cells (PBMCs) (45). 
In patients with chronic myelogenous leukemia (CML), percentage of M-
MDSCs was higher in high risk compared to those with low risk patients and 
correlated with decreased OS (7). In CLL patients, expansion of M-MDSCs was 
associated with decreased T-cell proliferation in a dose-dependent manner and 
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its levels negatively correlated with the absolute number of circulating T-
lymphocytes (7). 
1.5 Pharmacological interventions targeting MDSCs 
In mouse tumor models, it has been shown that T cell function can be 
restored, and tumor growth and development delayed by blocking MDSC 
suppression or through their depletion (15). Elimination of MDSC accumulation in 
tumors can help overcome T cell resistance (intrinsic resistance), improve anti-
tumor immunity and further potentiate T cell response to immune checkpoint 
blockade therapies such as anti-PD1/PD-L1 and anti-CTLA4 mAbs.   
To this end, various therapeutic strategies targeting MDSCs as an adjunct to 
conventional and immune therapies are being studied. These strategies have 
been broadly placed into four categories (30);  
a. Deactivation of MDSC immune suppressive function 
Phosphodiesterase-5 inhibitors such as sildenafil deactivate MDSCs by 
interfering with Arg1 and iNOS expression (30, 57). Nitro-aspirin (NO-aspirin) 
interferes with MDSC NO metabolism (30). Synthetic triterpenoids deactivate 
MDSC by reducing ROS. COX2 inhibitors reduce MDSC suppressive function by 
decreasing expression of Arg1. N-hydroxy-L-Arginine (NOHA) and N(G)-Nitro-L-
Arginine Methyl Ester (L-NAME) inhibit MDSC suppressive function by 
downregulating Arg 1 activity (30). Anti-glycan antibody and inhibitors of colony 
stimulating factors and their receptors block the migration of MDSC (30). Studies 
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have shown that histamine may stimulate GMCSF and IL-6 production via H1 
and H2 receptors on human PBMC in-vitro. Anti-histamines can block this activity 
and modulate MDSC suppressive function (30). IL-17 is important for recruitment 
of MDSCs to tumor sites. In tumor-bearing IL-17R and IFN-γR deficient mice, 
tumor development was inhibited which was associated with increased CTL 
infiltration of tumors and lower MDSC levels (30). A recent study showed that 
murine and human MDSC express Bruton’s tyrosine kinase (BTK). BTK inhibitor, 
ibrutinib (Imbruvica®) was able to inhibit the phosphorylation of BTK in these 
cells which resulted in impaired NO production, migration, and generation of 
MDSCs in vitro (31). 
b. Differentiation of MDSC into mature cells 
Agents such as all-trans retinoic acid (ATRA) and vitamins such as vitamin 
D3 or A enhance maturation of myeloid cells. DNA fragments that contain high 
frequency of unmethylated deoxycytosine-deoxyguanine dinucleotide (CpG) 
motifs (common in bacterial and viral DNA) can stimulate maturation of immune 
cells via Toll-like receptor 9 (TLR9) (30). Anti-microtubular agent, paclitaxel has 
been recently shown to promote differentiation of MDSCs into DC in vitro in a 





c.  Inhibition of MDSC development  
Nitro-Bisphosphonates (N-Bisphosphonates), platinum agents, and 
STAT3 inhibitors such as sunitinib (Sutent®) have been shown to block the 
formation of MDSCs.  
d. Depletion of MDSC 
Pyrimidine analogues like gemcitabine and 5‑fluorouracil (5-FU), and anti-
microtubule agents like docetaxel and paclitaxel have been found to reduce the 
number of splenic and tumor MDSCs without affecting the numbers of T cells, NK 
cells, macrophages, or B cells (5, 30, 57). Paclitaxel has also been shown to 
reduce Tregs and their inhibitory function (57). Treatment of tumor-bearing mice 
with ibrutinib resulted in a significant reduction of MDSC and improved the 
antitumor effect of anti-PD-L1 checkpoint blockade (31). 
1.6 Overview of metabolism in cancer and immune cells 
Otto Warburg in the early 20th century made an observation that rat 
hepatoma tissue slices maintained a higher rate of glucose catabolism than 
normal liver tissues even in the presence of oxygen (58, 59). This phenomenon 
was then called the “Warburg effect” and provides the basis for 2-[18F]fluoro-2-
deoxy-glucose positron emission tomography (PET) imaging (58, 59). 
Supporting the energy needs of the cell with glycolysis alone is a wasteful 
process. Catabolism of 1 mol of glucose to lactate yields only 2 mol of ATP; 
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however, 38 mol of ATP are produced on complete combustion of glucose to 
carbon dioxide and water in the presence of oxygen (58, 59). Cancer cells need 
not only ATP, but also need biosynthetic precursors from glycolytic intermediates 
in order to proliferate and invade (32). High glycolytic flux to pyruvate/lactate 
observed in tumors not only provides a ready supply of fructose-6-phosphate (F-
6-P) and glyceraldehyde-3-phosphate for shunting into de-novo nucleic acid 
synthesis but also decreases intracellular and extracellular pH, causing apoptosis 
in normal cells that express functional p53 (18, 32, 58-60).  
Hexokinase (HK) phosphorylates glucose to form glucose-6-phosphate 
(G-6-P), which can be converted into glycogen, oxidized by the pentose 
phosphate pathway (PPP) to generate NADPH or F-6-P. HK is the first 
irreversible but not rate-limiting step of glycolysis (58, 59). However, 6-
phosphofructo-1-kinase (PFK-1) is the irreversible and rate-limiting step of 
glycolysis which dictates the pace of glycolytic flux (Fig. 6) (58-60). PFK-1 
activity is modulated by several allosteric effectors such as adenosine 
triphosphate (ATP), citrate and hydrogen (H+) ions (58-60). ATP is the most 
potent inhibitor of PFK-1 and can directly inhibit PFK-1 as result of negative 
feedback when energy is abundant, also called the Pasteur effect (58, 59).  
PFK-1 activity is markedly increased in cancer cell lines and primary tumor 
tissues in situ; and the oncogenes ras and src activate PFK-1 in immortalized 
cells (58, 59). Fructose-2,6-bisphosphate (F2,6BP) allosterically activates PFK-1 
by shifting the conformational equilibrium of PFK-1 from a low to a high affinity 
state for F6P. F2,6BP can relieve the ATP induced allosteric inhibition of PFK1, 
32 
 
and thus allowing cancer cells to maintain high glycolytic flux despite the 
presence of physiologic ATP (58, 59). 
The steady-state concentration of F2,6BP is maintained by a family of 
bifunctional enzymes called 6-phosphofructo-2-kinase/fructose-2, 6-
bisphosphatases (PFK-2/FBPases), which phosphorylate F6P to F2,6BP or 
dephosphorylate F2,6BP back to F6P (Fig. 6) (58-60). The PFK-2/FBPases are 
encoded by four genes (PFKFB1–4). The enzymes encoded by the PFKFBi1, 
PFKFBi2 and PFKFBi4 genes display nearly equal kinase:phosphatase ratios. 
An inducible PFK2/FBPase encoded by the PFKFBi3 gene was recently 
identified to be activated by mitogenic, inflammatory and hypoxic stimuli and to 
display markedly reduced bisphosphatase activity (kinase:phosphatase ratio 740 





Figure 6. HIF-1α regulates the expression of PFKFB3 which synthesizes 
F26BP, a potent allosteric activator of PFK1. 
Metabolic adaptation to hypoxia in cancer cells is largely mediated through 
upregulation of transcription factor hypoxia inducible factor 1 alpha (HIF-1α) 
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which promotes increased expression of various glucose transporters and 
glycolytic enzymes such as Glut1 glucose transporter, HK2, PFK-1, pyruvate 
kinase M2 (PKM2) and lactate dehydrogenase A (LDH A) (Fig. 6) (32, 58, 59, 
61). Past studies have shown that exposure of Hep-3B human hepatoma cells to 
hypoxia or hypoxia mimics resulted in rapid induction of the PFKFB3 mRNA. This 
induction of PFKFB3 mRNA was completely abolished in mouse embryonic 
fibroblasts conditionally nullizygous for HIF-1α.  This suggests that the induction 
of PFKFB3 mRNA may be an essential component to the HIF-1α mediated 
adaptive response to hypoxia. In addition to stabilization of HIF-1α, loss of tumor 
suppressor gene phosphatase and tensin homolog (PTEN), and activation of 
oncogenes such as rat sarcoma (Ras) and PKB/Akt result in increased activity of 
PFKFB3 in cancers (58-61). The role of PFKFB3 in cancer development and 
progression is now well established.  
Upregulated aerobic glycolysis in immune cells was first reported in 
neutrophils. Activation of neutrophils resulted in upregulation of glycolysis, 
increased glucose consumption and increased oxygen consumption which was 
used primarily to produce ROS (62). It was shown that increased flux through the 
PPP generates nicotinamide adenine dinucleotide phosphate (NADPH), which is 
used by NOX enzymes to generate ROS (62-64). Studies evaluating the 
metabolic profile of macrophages and DCs have shown that inflammatory signals 
or activation is accompanied by increased glycolysis, lactate production and flux 
through PPP, and decreased oxygen consumption and TCA cycle activity (63, 
65, 66). Enhanced PPP provides biosynthetic precursors for purines and 
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pyrimidines. In macrophages and DCs stimulated with LPS and IFN-γ, 
expression of iNOS is increased which inhibits mitochondrial respiration through 
NO and results in metabolic shift away from oxidative phosphorylation (63, 67, 
68). 
Bone marrow cells from naïve wild type mice cultured in the presence of 
GM-CSF and IL-6 result in generation of MDSCs which are functionally and 
phenotypically similar to tumor derived MDSCs. These BM-MDSCs express high 
levels of Arg1 and iNOS. This is accompanied by increased L-glutamine and 
glucose metabolism by anaerobic glycolysis which results in the accumulation of 
TCA or Kreb cycle intermediates and lactate, and upregulated production of 
energy-rich nucleotides (69). These data show that MDSC maturation and 
immunosuppressive potential are associated with an increase in the central 
carbon metabolism activity level and bioenergetic status (69). 
Hammani et al showed that the increase in glucose uptake in BM-MDSCs 
resulted in cell specific concentration of F-6-P that was approximately 60% to 
70% that of G-6-P suggesting an upregulation of glycolysis. This was further 
associated with increased glucose consumption rate at 72 hours and decreased 
cell respiration. AMP-to-ATP ratio was up to 5-fold higher than in the control 
culture. The lactate-to-glucose yield started to increase at 32 hours and peaked 
after 80 hours. Conversely, the lactate-to-glucose yield remained stable (69). 
This accumulation of glycolysis intermediates may suggest that cells continue 
producing these intermediates without consuming them which can be observed 
at the time of initiation of cell death. However, cells were found to be alive. L-Arg 
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and lactate were continuously produced, suggesting that cells consumed these 
intermediates to support both the catabolic processes and the sparse synthesis 
of anabolism-related macromolecules (69). These results support the studies 
done by Ando et al. where it was seen that IL-6 enhances the expression of the 
glycolytic enzymes HK2 and PFKFB3 in mouse embryonic fibroblasts via the IL-
6/STAT3 pathway (69, 70). BM-MDSCs upregulate glycolysis despite non-limiting 
oxygen conditions and produce lactate rather than obtaining high energy yields 
from respiration.  
Accumulation of TCA cycle intermediates such as fumarate and succinate 
is associated with the inhibition of HIF hydroxylases resulting in the stable 
expression of HIF-1α (24, 63). This is in concert with recent findings reported by 
Corzo et al that MDSCs express HIF-1α to adapt to the quasi-hypoxic conditions 
encountered in tumors (11). Decreased respiration in BM-MDSCs in the 
presence of GM-CSF and IL-6 is likely related to HIF-1α expression (69). Another 
study had demonstrated that monocytes exposed to hypoxia rapidly stimulate 
glycolysis by activating PFKFB3 through phosphorylation of serine (58). In 
addition, accumulation of fumarate suggests that L-Arginine is being continuously 
synthesized which supports a permanent immunosuppressive activity (69). 
GM-CSF has been shown to induce a rapid glucose-dependent 
extracellular acidification that is regulated by protein kinase C (PKC) and the 
sodium/proton antiporter (69, 71). Furthermore, iNOS activity is associated with 
an increased glucose consumption rate, increased glycolysis and PPP, and the 
inhibition of oxidative phosphorylation in zymosan (a glucan with repeating 
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glucose units and aTLR2 agonist) treated macrophages (69). MDSCs tend to 
behave like tumors when it comes to their bioenergetics and metabolic needs. 
These findings substantiate the findings that M-MDSCs express and stabilize 
HIF-1α to help adapt to oxygen poor TME. 
Another recent study demonstrated a link between upregulated glucose 
metabolism and fatty acid oxidation (FAO) to immunosuppressive phenotype of 
MDSCs (53, 69). Authors showed that this was accompanied by an increase in 
the mitochondrial mass, upregulation of the enzymes involved in glycolysis and 
FAO and increase in oxygen consumption rate (53, 69). Authors also 
demonstrated that pharmacologic inhibition of FAO blocked the 
immunosuppressive function of PMN-MDSCs resulting in delayed tumor growth 
and improved T cell activity (53).   
Yet another recent study showed that the activation of the inflammatory 
response is accompanied by a metabolic shift to anaerobic glycolysis for the 
reasons as described above. Authors reported that mechanistic target of 
rapamycin complex 1 (mTORC1) -dependent glycolysis is critical for the lineage 
commitment of M-MDSCs but not PMN-MDSCs. It was observed that mTORC 
inhibition or deletion resulted in significant decline in glycolysis during MDSC 
differentiation as evidenced by the lower glucose uptake and glycolysis-related 
enzymes like HK1, HK2, PFK1, PKM2 and LDHA. 2-DG, which blocks HK activity 
significantly, inhibited M-MDSC development from bone marrow. On the other 
hand, metformin which is an enhancer of the glycolytic pathway significantly 
enhanced M-MDSC differentiation and rescued rapamycin-mediated poor 
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differentiation of MDSCs in vitro and in vivo. Thus, rapamycin is able to block M-
MDSC differentiation from bone marrow precursors mainly through mTORC1-
dependent glycolysis pathway (72). 
Glycolysis results in the production of pyruvate and under normoxic 
conditions; pyruvate is converted to acetyl-CoA by the enzyme pyruvate 
dehydrogenase (PDH). Acetyl-CoA then enters into the TCA or Krebs cycle and 
results in the production of more ATP and other biosynthetic precursors. 
However, under anaerobic conditions, pyruvate is converted to lactic acid by the 
enzyme lactate dehydrogenase (LDH) (73). Tumors preferentially convert 
pyruvate into lactate instead of entering into the TCA cycle, even under normoxic 
conditions (73). In addition, lactate is also produced as a by-product of 
glutaminolysis where glutamine is converted to glutamate, then to α-
ketoglutarate, followed by conversion into malate, which is then oxidized into 
pyruvate in the cytosol. This pyruvate is then converted to lactate allowing the 
coupled regeneration of NAD+ and the production of ATP via the glycolysis 
pathway. This allows cells to produce ATP under hypoxic conditions and places 
glucose, rather than fatty acids or amino acids, in the unique position of being 
essential for cells to survive (73-75). LDH-A is induced by different oncogenes, 
including c-myc and, thus, providing a link between malignant transformation and 
metabolic pathways (73, 76). 
Lactate generation contributes to the acidic TME that increases the 
frequency of MDSC accumulation, induces tolerogenic T cells and decreased 
CTL and NK cell activity, stimulates angiogenesis and promotes metastasis (18, 
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32, 73). Lactic acid can also be actively produced in immune-regulatory myeloid 
cells by cytokine-activated, anaerobic glycolysis (33). Lactate accumulation 
affects DC maturation and results in the arrested development of APCs from 
myeloid progenitors (18, 32, 73). Further, it affects CTL activity through 
polarization of immune responses to a more pro-inflammatory profile consisting 
of Th17 and Th23 phenotypes (18, 32). Lactate can also induce transcription of 
Arg1 gene leading to increased arginase expression and suppressed T cell 
activity (73). Studies have also shown that when mice are subjected to a 
ketogenic diet, essentially a suboptimal surrogate for LDH-A inhibition, tumors 
have higher frequency of T effector cell infiltration further providing evidence that 
high lactate levels can effect T cell recruitment (77). Lactate has also been 
shown to be an endogenous inhibitor of histone deacetylases (HDAC), regulating 
the transcription of genes involved in metabolism and immune responses, such 
as natural cytotoxicity triggering receptor 1 (NCR1), which encodes NK-cell 
activating receptor (77). High levels of LDH or lactate in the peripheral blood of 
patients with advanced melanoma have been shown to predict poor outcome 
with ipilimumab (2, 56, 73). 
1.7 Hypoxia  
Hypoxia is one of the hallmarks of the tumor microenvironment (TME). It is 
the consequence of insufficient blood supply and rapid tumor growth. 
Subsequently, cells adapt to the low oxygen environment and upregulate the 
transcription of genes required for cell survival and metabolism under these 
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conditions. HIF-1α promotes the metabolic switch to glycolysis so cells can 
continue to produce ATP when oxygen is limited. HIF plays a critical role in the 
modulation of cellular responses, and recently, also the anti-tumor immune 
responses (37). 
HIF-1α is a predominant oxygen sensing subunit in hematopoietic cells. 
HIF-1α activity is regulated by post-translational modification of oxygen-
dependent degradation domain (ODD). When oxygen levels are above 5%, 
hydroxylation of the proline residues at positions 402 and 564 in the ODD enable 
binding of the ubiquitination ligase von Hippel-Lindau (VHL) tumor suppressor 
protein leading to the degradation of HIF-1α by the proteosome. However, at 
oxygen levels below 5%, hydroxylation is inhibited resulting in stabilization of 
HIF-1α allowing it to translocate to the nucleus, bind to HIF-1β and regulate 
transcription (37). In activated macrophages, it has been shown that mTOR helps 
cells meet high metabolic needs by increasing expression of HIF- 1α which then 
increases the expression of glycolytic and inflammatory genes (78, 79). 
In anaerobic glycolysis, pyruvate, which is an end product of glycolysis is 
metabolized to lactate instead of feeding into the TCA cycle to boost subsequent 
oxidative phosphorylation (80). HIF-1α induces the expression of genes such as 
the glucose transporter GLUT1 and enzymes involved in glycolysis by binding to 
their hypoxia response elements (HRE) (81-83). It also induces the expression of 
LDH which catalyzes the production of lactate from pyruvate limiting the supply of 
acetyl-CoA for the TCA cycle (84). It has also been shown to suppress oxidative 
phosphorylation in mitochondria. (11). HIF-1α expression is also stabilized by the 
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lactic acid produced by anaerobic glycolysis in cancer cells (85). In 
macrophages, Colegio et al showed that lactic acid can stabilize HIF-1α even 
under normoxic conditions and stimulate the transcription of VEGF and Arg1 
genes (85). Also in macrophages, it has been shown that iNOS is a hypoxia-
inducible gene (86). Hypoxia induced iNOS-HRE activity and activated the iNOS 
promoter and induced iNOS transcription and mRNA expression (86). Based on 
data from studies done in macrophages, hypoxia appears to be a common 
denominator for the metabolic shift to glycolysis and production of lactic acid and 
ultimately upregulation of inflammatory genes such as Arg1 and iNOS (Fig. 4).    
Hypoxia in the TME plays a critical role in the regulation of MDSC function 
via upregulation of HIF-1α.  Exposure of splenic MDSCs to hypoxia can mimic 
the effects of the TME on these cells by inducing a dramatic up-regulation of 
iNOS and Arg1 expression and downregulation of NOX2 and ROS (10, 11, 15, 
17, 21, 24, 25, 37, 42, 51, 55). Further, these cells functionally differentiate from 
antigen-specific to antigen-nonspecific T cell suppressors (Fig. 7) (10, 11, 15, 17, 
21, 24, 25, 37, 42, 51, 55). TME due to hypoxia and low pH does not support the 
survival of PMN-MDSCs (24). 
Further, under hypoxic conditions and in the presence of TDSFs, splenic 
M-MDSCs differentiate to tumor associated macrophages (TAMs) which express 
F4/80 in mice and CD68 in humans resulting in further immune suppression and 
a tolerogenic state (Fig. 7) (1, 11, 16, 17, 20, 24, 37). These macrophages do not 
show preferential polarization to either the M1 or M2 subtype and express high 
levels of genes associated with both such as CXCL10 and CD206 typical of M1 
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and M2 activation, respectively. HIF-1α-deficient MDSCs have reduced ability to 
differentiate in to macrophages and instead acquire markers of DC (8, 37).  
 
Figure 7. Hypoxia and MDSC. (A) MDSCs from HIF-1α knock-out mice result in 
reduced antigen non-specific suppression of T cells as compared to MDSCs from 
WT mice. (B) Hypoxia results in further expansion of MDSCs and macrophages 
(11). 
Upregulation of HIF-1α inhibits effector functions of tumor-infiltrating 
lymphocytes (TILs), promotes development of Th17 cells and Treg recruitment to 
the tumor site (37). HIF-1α also regulates the expression of genes involved in 
angiogenesis, apoptosis, proliferation, cell cycle progression, cancer stem cell 
self-renewal and metastasis (37).  
1.8 MDSCs – in vitro models  
One of the major difficulties with MDSC studies is the ability to obtain 
adequate number of cells from in vivo models. Studies by Marigo et al. have 
demonstrated that the combination of GM-CSF and IL-6 can allow for a rapid 
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generation of MDSCs from mice and human bone marrow (14). In mice, these 
bone marrow derived MDSCs (BM-MDSCs) are highly tolerogenic, suppress T 
cell activity and have a functional phenotype similar to tumor MDSCs (14, 26, 
69). In another study, GM-CSF and IL-6 combination was used to generate 
suppressive human CD33pos myeloid cells ex vivo. Following adoptive transfer, 
BM-MDSCs generated from mouse embryonic stem cells and bone marrow 
hematopoietic progenitor cells prevented alloreactive T-cell-mediated GVHD 
(87). LPS has also been shown to induce BM-MDSCs from bone marrow 
progenitor cells and on adoptive transfer suppressed allergen-induced airway 
inflammation in recipient mice (24). Mouse bone marrow-derived IL4Rαpos MDSC 
induced following incubation with GM-CSF+G-CSF or GM-CSF+IL-6 or IL-13 
consist of a mixture of immature cells and exhibit immune suppressor activity 
(19). Human MDSCs induced following incubation of PBMC with GM-CSF+IL-6 
or GM-CSF+IL-1β, PGE2, TNF-α and VEGF resulted in immune suppressive 
cells that were CD33, CD11b and CD66b positive and HLA-DR negative, and 
inhibited the proliferation and IFN-γ production by autologous human T cells after 
anti-CD3/CD28 stimulation (3, 19). 
BM-MDSCs obtained following incubation with GM-CSF and IL-6 resulted 
in a significant upregulation of ARG1 and iNOS activity after 16 and 24 hours, 
respectively (69). This was followed by changes in glycolytic intermediates and 
cell respiration levels at 32 hours. BM-derived MDSCs exhibit 
immunosuppressive potential only after 48 to 72 hour exposure to cytokines (69). 
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Co-culture of CD14pos cells obtained from normal donor PBMCs with 
melanoma cell lines such as A375 or EST can allow for rapid generation of 
MDSCs in vitro (26, 50). On multicolor flow cytometry analysis, the percentage of 
CD14posCD11bposCD33posHLA-DRlow cells was substantially increased in 
melanoma-monocyte co-cultures compared with that in monocytes cultured in the 
absence of melanoma cells (26, 50). CD11bpos cells purified from the melanoma-
monocyte co-cultures exhibited a significant reduction in HLA-DR and increase in 
CD14, CD33, PD-L1, CD86 and DC-SIGN (CD209) markers (26, 50). Phenotype 
of A375-MDSCs was similar to circulating M-MDSCs obtained from late-stage 
malignant melanoma patients (26, 50). Separation of melanoma cells and 
monocytes in a transwell system did not result in the upregulation of CD14 or 
CD11b as compared with control cultured monocytes, which points to the fact 
that cell-to-cell contact or mechanisms that require close proximity to tumor cells 
were necessary (26). 
Importantly, it should be noted that cryo-preservation can affect not only 
MDSC phenotype but also their functional activity. Studies have shown that 
MDSCs sorted from fresh blood samples of cancer patients suppressed the 
proliferation of autologous T cells. However, when MDSCs were isolated from 
frozen PBMCs, they failed to suppress T cell activity (7). 
1.9 MDSCs in other disease states 
MDSC are present in a low frequency in healthy individuals, but are 
increased in bacterial, viral and parasitic infections, and trauma to facilitate 
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wound healing (26). There is growing evidence that MDSCs play a central role in 
different models of autoimmune diseases such type 1 diabetes mellitus, auto-
immune arthritis, colitis, alopecia areata, myocarditis, GVHD or experimental 
autoimmune encephalomyelitis (EAE) (19, 27). 
Chronic infections such as trypanosomiasis, toxoplasmosis, candidiasis, 
and leishmaniasis results in expansion of M-MDSCs and mediates suppression 
through NO secretion (6, 49). In lupus-prone MRL-Faslpr mice, MDSC 
suppressive effect on CD4 T cell proliferation was blocked by an Arg1 inhibitor 
(49). Sepsis results in MyD88-dependent expansion of MDSCs, T cell 
suppression and Th2 polarization (49).   
In an inflammatory bowel disease model, the repeated transfer of antigen-
specific T cells resulted in an increase in the frequency of iNOS and Arg1-
expressing MDSCs in spleen and intestine (49). However, co-transfer of MDSCs 
with specific CD8 T cells ameliorated enterocolitis suggesting a direct 
immunoregulatory effect of MDSCs (49). In a Theiler’s murine encephalomyelitis 
virus mouse model of multiple sclerosis (MS), M-MDSC depletion resulted in an 
increase of virus specific CD4 and CD8 T cell responses, and an increased 
expression of IFN-γ and IL-17, and a decreased expression of IL-10 in the CNS 
(49). In vivo transfer of MDSCs ameliorated EAE which was followed by 
significantly decreased demyelination, and delayed disease onset through the 
inhibition of Th1 and Th17 immune responses (49). In obese mice, MDSCs have 
been shown to counter proinflammatory immune responses in the liver and 
adipose tissue through suppression of CD8 T cell proliferation, induction of 
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apoptosis, and skewed differentiation of macrophages into insulin-sensitizing, 
alternatively activated M2 macrophages (49). MDSCs together with Tregs are 
also involved in the regulation of immune response during organ transplantation 
and GVHD (49). MDSCs, generated in vitro or in vivo, alleviate GVHD in murine 
allogeneic bone marrow transplantation models (49). Studies have shown a 
significant correlation between the MDSC levels, disease progression, and the 
response of patients to antiviral therapy in patients with chronic Hepatitis C (49). 
In HIV, the presence of M-MDSCs in peripheral blood correlated with prognostic 
HIV-1 disease markers such as HIV-1 viral load and CD4 T cell loss. M-MDSCs 
from HIV-1 positive patients suppressed T cell responses in both HIV-1–specific 








2.0 METHODS AND MATERIALS 
2.1 Media and reagents 
Tumor cell lines were cultured in Dulbecco's Modified Eagle Medium 
(DMEM) supplemented with 100 mg/ml penicillin and streptomycin (Gibco, 
Carlsbad, CA), 1% sodium glutamate (Gibco, Carlsbad, CA) and 10% heat-
inactivated FBS (Life Technologies, Carlsbad, CA). Splenic MDSCs were 
cultured in Roswell Park Memorial Institute medium (RPMI) 1640 medium 
supplemented with 100 mg/ml penicillin and streptomycin, 1% sodium glutamate, 
50 mM beta-mercaptoethanol (BME) (Gibco, Carlsbad, CA), and 10% heat-
inactivated FBS. Bone marrow-derived MDSCs were cultured in the same media 
as for splenic MDSCs but with the addition of 50 µM HEPES. Human MDSC and 
CD14pos cells were cultured in Iscove's Modified Dulbecco's Medium (IMDM) 
supplemented with 100 mg/ml penicillin and streptomycin, 1% sodium glutamate, 
and 10% human AB sera (Sigma-Aldrich, St. Louis, MO).  
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2.2 Patient samples and cell lines 
Peripheral blood was collected from 33 patients with stage III-IV 
melanoma, and from eight normal donors. Melanoma patients included in the 
study were treatment naïve or had not received any active treatment in the six 
months prior to when their samples were collected. Informed consent was 
obtained prior to patient sample collection by the staff of the JG Brown Cancer 
Center Biorepository and covered under University of Louisville IRB protocol 
number 08.0388. Peripheral blood mononuclear cells (PBMC) were isolated from 
the melanoma patients using cell preparation tube (BD Vacutainer® CPTTM). For 
in vitro induction of human MDSC experiments, PBMC were isolated from normal 
donors by density gradient centrifugation (Ficoll-Hypaque, GE) within 2 hours of 
sample collection.  
The melanoma cell lines A375 (ATCC® CRL-1619TM) and B16-F10 
(ATCC® CRL-6475TM) were purchased from the ATCC and maintained in 
complete DMEM as described above. Cell lines were never cultured for longer 
than six to eight weeks. All of cell line stocks came from thawed vials that were 
frozen at passage two after they were received from the ATCC. A375 and B16-
F10 cell lines were authenticated by the ATCC cell bank using short tandem 
repeat profiling. 
2.3 Mice  
Wild-type (WT) male C57BL/6 mice were purchased from Envigo (Dublin, 
VA) and the Jackson Laboratory (Bar Harbor, ME). Mice were six-eight weeks 
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old. OT-II CD4 ovalbumin TCR-Tg mice were purchased from the Jackson 
Laboratory. All mice were kept in pathogen free conditions and handled with the 
approval of the Institutional Animal Care and Use Committee at the University of 
Louisville (Louisville, KY). 
2.4 Tumor models 
C57BL/6 WT mice were injected subcutaneously (s.c.) with B16-F10 
melanoma cell line (1 × 105/mouse) in to their left flanks. Tumor measurements 
were performed with digital calipers every three to four days. Mice were 
sacrificed at 18-21 days after tumor challenge or when the tumor diameter 
reached 15-18 mm in size. Tumor volumes were calculated based on the 
formula=length × width2/2. Starting day 11 post-implantation, mice were given 
intra-peritoneal injections of PFK-158 (60 mg/kg) for a total of four doses at day 
11, 13, 16 and 18. On day 19, spleens from vehicle control and PFK-158 treated 
mice were harvested and splenic M-MDSCs were sorted by magnetic bead 
separation for functional assay as described below.  
2.5 Isolation of Splenic Myeloid Derived Suppressor cells (MDSCs) 
Tumor-bearing C57BL/6 WT mice were sacrificed 18–21 days after tumor 
challenge. To collect MDSCs, single cell suspensions were prepared from 
spleens, and red cells were removed using ammonium chloride (ACK) lysis 
buffer. Post-ACK lysis, cells were washed twice with RPMI 1640 medium 
containing 10% FBS. Single-cell suspensions were then treated with Fc-blocker 
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for 10 minutes on ice. GR1highLy-6Gpos PMN- and GR1dimLy-6Cpos monocytic-
MDSCs were isolated from the spleens using the mouse MDSC isolation kit 
(Miltenyi Biotec, San Diego, CA). The purity of cell populations was confirmed by 
flow cytometry and was >98%. 
2.6 Hypoxic cell culture conditions 
Freshly isolated M-MDSCs from the spleens of tumor-bearing mice were 
cultured for 16, 24 and 48 hours in 25% B16-F10 tumor cell conditioned media 
(TCCM) under normoxic and hypoxic conditions (1% oxygen with 5% carbon 
dioxide) as described previously (11). For functional assays, cells were cultured 
under normoxia, and hypoxia with and without addition of PFK-158 (5 µM) for 48 
hours.   
2.7 Mouse bone marrow–derived MDSCs (BM-MDSCs) 
Tibias and femurs from C57BL/6 WT mice were removed using sterile 
techniques, and bone marrow was flushed with cold PBS. To obtain bone 
marrow–derived MDSCs, bone marrow cells were cultured for four days with GM-
CSF (40 ng/mL) (Peprotech, Rocky Hill, NJ), and IL6 (40 ng/mL) (Peprotech, 
Rocky Hill, NJ), as previously described (14). Bone marrow cultures were treated 
with 0.1% DMSO (vehicle control) and PFK-158 on day zero and day three of the 
culture period. The dose of PFK-158 was 5 µM on day zero and 2.5 µM on day 
three. For functional assays, whole bone marrow-derived MDSCs were used. 
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Using mouse MDSC isolation kit (Miltenyi) both PMN- and M-MDSCs were 
sorted from these bone marrow cultures. Sorted cells were then treated with 
vehicle control (0.1% DMSO) and PFK-158 (5 µM) overnight and then used for 
functional assays and other mechanistic studies.   
2.8 Melanoma patient MDSC 
CD14pos monocytic MDSCs from melanoma patients were isolated from 
PBMC using anti-CD14 magnetic microbeads and the autoMACS Pro Separator 
(Miltenyi Biotec, San Diego, CA), per manufacturer's protocol. One million M-
MDSCs were plated in complete IMDM per well in a six-well plate (BD Falcon) 
and treated with PFK-158 (5 µM) and DMSO (0.1% vehicle control) for 16-18 
hours. For functional experiments, autologous T cells were isolated from PBMCs 
using the Pan T-cell Isolation Kit (Miltenyi Biotec).  
2.9 In vitro generation of human MDSCs 
One million CD14pos cells isolated from PBMCs from normal donors were 
co-cultured with 5 × 105 A375 melanoma cells in 3.5 mL complete IMDM per well 
in a six-well plate for three days (26). Tumor/monocyte co-cultures were treated 
twice with PFK-158 (5 µM on day zero and on day two) or 0.1% DMSO (vehicle 
control). A375 co-cultured monocytes (both vehicle control and PFK-158 treated) 
and control monocytes cultured without tumor cells were harvested by gently 
scraping after three days of culture and CD11bpos cells were purified by anti-
CD11bpos microbeads and MS columns (Miltenyi Biotec). Further, A375 
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melanoma and CD14pos cells were co-cultured for three days without the addition 
of PFK-158. CD11bpos cells were purified as above and then treated with PFK-
158 (5 µM) and vehicle control for 16-18 hours in 2 mL complete IMDM in six-well 
plates. Following day, cells were harvested and washed prior to functional 
assays and other mechanistic studies. 
2.10 Functional Assays 
Freshly isolated PMN- and M-MDSCs (1 × 106 cells/well) from the spleens 
of B16-F10 tumor bearing C57BL/6 WT mice were cultured in 1 mL complete 
RPMI and treated with PFK-158 (5 µM) or DMSO (vehicle control) for 16-18 
hours in flat-bottom 24-well plate. Cells were harvested, washed and then co-
cultured with splenocytes from OT-II mice in triplicates in flat-bottom 96-well 
plates in the presence of the ovalbumin (200 µg/mL; Sigma-Aldrich) at 1:2, 1:4 
and 1:8 ratios for an additional 72 hours. Eighteen hours before harvesting, co-
cultures were pulsed with [3H]-thymidine (1 uCi/well; MP Bioscience). [3H]-
thymidine incorporation was counted using a liquid scintillation counter and 
relative counts per minute (cpm) were used to determine percent inhibition of 
proliferation. Similarly, whole bone marrow-derived MDSCs were co-cultured with 
splenocytes from OT-II mice in the presence of ovalbumin at 1:4, 1:8 and 1:16 
ratios for 72 hours and then pulsed with [3H]-thymidine eighteen hours prior to 
harvesting. Percent inhibition of proliferation was determined as above.  
To determine the suppressive activity of PMN- and M-MDSCs sorted from 
bone marrow-derived MDSCs, and splenic M-MDSCs cultured under hypoxic 
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conditions, both treated and non-treated cells were co-cultured with 5 mmol/L 
carboxyfluorescein succinimidyl ester (CFSE, Invitrogen) labelled splenocytes 
from C57BL/6 WT mice in an anti-CD3 coated flat-bottom 96-well plate for 72 
hours with addition of anti-CD28. Cells were then harvested and stained with 
CD4 and CD8 APC flourochrome (Biolegend, San Diego, CA), and proliferation 
was measured using flow cytometry.  
To evaluate the suppressive functions of melanoma patient–derived 
MDSCs and A375-MDSCs, autologous T cells were labeled with 5 mmol/L CFSE 
and seeded at 100,000 cells per well in a 96-well U-bottom plate. For melanoma 
patient samples, CD14pos cells pretreated with vehicle control and PFK-158 (5 
µM) for 16-18 hours were added to T cells at 2:1 and 1:1 ratios. T cells were 
activated by the addition of anti-CD3/CD28 monoclonal antibody (mAb) coated 
beads (Invitrogen) per well for four days. T-cell activation was measured by flow 
cytometry, and IFN-γ concentrations in the supernatants were determined by 
ELISA. Controls included non-activated T cells or T cells activated with beads 
alone. For A375-MDSCs, CD11bpos cells purified from tumor co-cultures with 
vehicle control and PFK-158 treatment or CD11bpos cells treated with PFK-158 
post-purification were added to T cells at ratios of 1:1 and 1:2, and T-cell 
activation was measured as above. 
2.11 Arginase assay 
Arginase activity was quantified in cell lysates by measuring the 
production of urea using the QuantiChrom™ arginase assay kit as per 
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manufacturer’s instructions (DARG-200, BioAssays Systems). One million cells 
per condition were lysed for 10 minutes in 100 µL of 10 mM Tris-HCl (pH 7.4) 
containing 1 µM pepstatin A, 1 µM leupeptin, and 0.4% (w/v) Triton X-100. Cell 
lysates were centrifuged at 14,000 g at 4˚C for 10 min. Supernatants were used 
to measure arginase activity following incubation with arginase reaction mix and 
urea reagent. OD was measured at 430 nm.     
2.12 Nitric oxide assay 
Supernatants from PFK-158 and vehicle control treated cell cultures were 
collected. To detect nitric oxide (NO), equal volumes of culture supernatants (100 
µl) were incubated with Greiss reagent (Sigma Aldrich) at room temperature (RT) 
for 15 minutes in a 96-well plate. Absorbance at 550 nm was measured using a 
microplate plate reader (BioTek, Winooski, VT). NO concentrations were 
determined by comparing the absorbance values for the test samples to a 
standard curve generated by serial dilution of 0.25 mM sodium nitrite. 
2.13 ROS detection 
Oxidation-sensitive dye dichlorodihydrofluorescein diacetate (DCFDA, 
Molecular Probes/Invitrogen, Carlsbad, CA), was used to measure ROS 
production by MDSCs. Cells were incubated at 37°C in RPMI in the presence of 
5 µM DCFDA for 30 min. For induced activation, cells were simultaneously 
cultured, along with DCFDA, with 30 ng/ml phorbol 12-myristate-13-acetate 
55 
 
(PMA) (Sigma, St. Louis, MO). The mean fluorescence intensity (MFI) of 
intracellularly retained DCF in CD14pos cells was determined by flow cytometry. 
2.14 Lactate assay 
Lactate production was measured using colorimetric assay (Biovision, 
CA). Supernatants collected from the PFK-158 and vehicle treated groups were 
filtered through a 10 kDa molecular weight spin filter (Amicon Ultra) to 
deproteinize and remove LDH present in FBS containing medium and diluted in 
dH2O. Equal volumes (50 µL) of the supernatants were incubated with reaction 
mix containing the assay buffer, enzyme mix and probe at RT for 30 min. 
Absorbance at 570 nm was measured using a microplate plate reader (BioTek).  
2.15 F-2,6-BP assay 
Intracellular concentration of F-2,6-BP was determined based on 
previously described protocol (88). Briefly, cells were washed in PBS and lysed 
in NaOH/Tris acetate by heating at 80°C for 5 minutes. Lysates were neutralized 
to pH 7.2 by adding ice-cold acetic acid and HEPES. Samples were incubated at 
25°C for 2 minutes in the following assay mixture: 50 mM Tris, 2 mM Mg2+, 1 mM 
F6P, 0.15 mM NAD, 10 U/l PPi-dependent PFK-1, 0.45 kU/l aldolase, 5 kU/l 
triosephosphate isomerase and 1.7 kU/l glycerol-3-phosphate dehydrogenase 
(Sigma). In total, 0.5 mM pyrophosphate was added and the rate of change in 
absorbance (OD=339 nm) per minute was followed for 5 minutes. F-2,6-BP was 
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calculated based on a calibration curve produced by measuring 0.1 to 1 pmol of 
F-2,6-BP (Sigma) and normalized to total cellular protein. 
2.16 Glucose uptake assay 
Glucose uptake in cells was measured using cell-based glucose uptake 
assay kit (Abcam, ab204702). Bone marrow-derived M-MDSC (2 × 106 cells) 
were cultured in 400 µL of RPMI medium with 0.5% FBS with vehicle control and 
PFK-158 for one hour at 37˚C with 5% CO2. Cells were then centrifuged at 400 x 
g for 5 minutes, media was removed and 400 µL of glucose uptake mix 
containing 376 µL of RPMI with 0.5% FBS, 4 µL of glucose tracker reagent, 20 
µL of glucose tracker enhancer, and PFK-158 and vehicle control was then 
added and cells incubated for additional 30 minutes under same conditions. Cells 
were then washed with ice cold analysis buffer and flow cytometry analysis was 
performed where MFI was quantified in FL1 channel.    
2.17 Bioenergetic analysis 
The Seahorse XF96e Extracellular Flux Analyzer (Seahorse Bioscience, 
North Billerica, MA) was used to perform bioenergetic analysis of MDSCs. The 
Extracellular Flux Analyzer enables simultaneous live cell measurement of 
oxygen consumption rate (OCR) which is an indicator of mitochondrial 
respiration, and extracellular acidification rate (ECAR) which is an indicator of net 
proton loss during glycolysis. Bioenergetic analysis was performed comparing 
fresh bone marrow cells and fresh CD14pos monocytes to their respective in vitro 
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induced MDSC counterparts and between vehicle and PFK-158 treated MDSCs. 
Cells were seeded in growth media (1 × 105 cells/well) into the XF96e cell culture 
plate and allowed to loosely attach for 1-2 hours. Cell culture media was then 
gently replaced with XF media (Seahorse Bioscience), lacking sodium 
bicarbonate and FBS, after prior washing with XF media. Cell culture plate was 
placed in a non-CO2 37°C incubator for 1 hour, prior to start of the experiment. 
OCR and ECAR were measured over a 3 or 5 minute periods, followed by 3 or 5 
minute mixing and re-oxygenation of the media. Basal rate measurements were 
taken prior to injection of pharmacological manipulators of mitochondrial 
respiratory chain proteins. Following the determination of basal OCR reading, 
oligomycin A is applied to inhibit proton (H+) flow through ATP synthase, 
essentially blocking all ATP-linked oxygen consumption. Maximal respiration is 
initiated by exposing cells to carbonyl cyanide-ptrifluoromethoxyphenyl 
hydrazone (FCCP), an ionophore that transports H+ across the mitochondrial 
membrane leading to collapse of membrane potential and rapid consumption of 
O2. Antimycin A prevents mitochondrial respiration by blocking complex III 
(Ubiquinone:Cytochrome b-c complex). Program was set to first inject 1 µM 
oligomycin A (Sigma), followed by 750 nM FCCP (Sigma) and at last, 1 µM 
antimycin A (Sigma) was injected. Three measurements of OCR/ECAR were 





2.18 Western blotting 
Cells were lysed with radioimmunoprecipitation assay (RIPA) buffer in the 
presence of protease and phosphatase inhibitors. Protein lysates were subjected 
to 8-20% gradient SDS-PAGE gel (BioRad) and transferred to PVDF 
membranes. Membranes were probed with appropriate specific antibodies 
overnight at 4°C. Membranes were washed and incubated for 2 hours at RT with 
secondary antibody conjugated with peroxidase. Results were visualized by 
chemiluminescence detection using Amersham ECL Prime western blotting 
detection reagent (GE Healthcare Life Sciences). To confirm equal loading, 
membranes were stripped and reprobed with antibody against β-actin (Santa 
Cruz Biotechonology, Santa Cruz, CA). Anti-arginase 1 antibody was obtained 
from Santa Cruz Biotechnology, anti-NOX2 and NOX4 antibodies were obtained 
from Cell Signaling Technology (Boston, MA), anti-HIF-1α antibody was obtained 
from Novus Biologicals (Littleton, CO) and anti-PFKFB3 antibody was obtained 
from Proteintech (Rosemont, IL). 
2.19 ELISAs 
IFN-γ concentration was measured using ELISA in the supernatants from 
T-cell:MDSC co-cultures using instructions as per the manufacturer. ELISA kit 




2.20 RNA extraction and quantitative real-time PCR 
RNA was extracted from MDSCs using Trizol (Invitrogen, Frederick, MD) 
as per manufacturer’s protocol. cDNA was synthesized using iScript cDNA 
synthesis kit (BioRad). Quantitative real-time PCR (qRT-PCR) was performed 
using TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, CA), 
and target gene assay mix containing sequence-specific primers and 6-
carboxyfluorescein (6-FAM) dye–labeled TaqMan minor groove binder (MGB) 
probe (Applied Biosystems, Foster City, CA). Amplification with an 18S 
(Hs99999901.s1; VIC; Applied Biosystems) endogenous control assay mix was 
used for controls. qRT-PCR was carried out in triplicates for each sample. Data 
quantitation was performed using the relative standard curve method. Expression 
levels of the genes were normalized by 18S mRNA. The change in gene 
expression was measured by calculating the fold change in threshold (ΔΔCt), 
where ΔCt = Cttarget gene minus Cthousekeeping gene, ΔΔCt = ΔCtinduced minus ΔCtreference 
and fold change = 2(-∆∆Ct). All primers used are listed in Table 1. 
Table 1. Primers used in qRT-PCR analysis of different gene expressions in 
this study. 
Genes Primer ID Dye 
Mouse Arginase 1 Mm00475988_m1 FAM-MGB 
Mouse iNOS/Nos2 Mm00440502_m1 FAM-MGB 
Mouse LDHA Mm01612132_g1 FAM-MGB 
Human Arginase 1 Hs00163660_m1 FAM-MGB 
Human iNOS/NOS2 Hs01075529_m1 FAM-MGB 





2.21 Antibodies and flow cytometry 
Untreated or PFK-158–treated murine and human MDSCs were stained 
using anti-mouse and anti-human antibodies according to the manufacturer's 
recommendations. Details on flow cytometry antibody panels are provided in 
Tables 2 and 3. We assessed the frequency and phenotype of MDSCs in all the 
models described above both in mice and humans. Cells were harvested, 
washed, counted and resuspended in FACS buffer. 0.5 million cells live cells (by 
trypan exclusion) were stained with multi-color Ab panel. Following the initial 
FSC/SSC discrimination to exclude dead cells and aggregates, the gate was set 
on CD45pos leukocytes to exclude the tumor cells and then on CD11bpos cells. 
Next, we gated on the subpopulations defined as MDSC in humans: CD14, CD33 
and HLA-DR cells and their combinations (Table 2), and in mice: GR1 (Table 3). 
Gates were set based on isotype controls. 
Table 2. Human MDSC flow antibody panel 
Antibody Specificity/Marker Stained Flurochrome Source 
CD4 APC Biolegend 
CD8 APC Biolegend 
CD11b FITC Biolegend 
CD14 PE Biolegend 
CD33 PerCP-Cy5.5 Biolegend 
HLA-DR APC Biolegend 
CD45 APC-Cy7 Biolegend 
 
Table 3. Mice MDSC flow antibody panel 
Antibody Specificity/Marker Stained Flurochrome Source 
CD11b FITC Biolegend 




2.22 Statistical analysis 
GraphPad Prism 5.0 software (GraphPad Prism Software, Inc., La Jolla, 
CA) was used for all statistical analyses. Comparisons between groups were 
done by two tailed Student’s t tests. For all tests, statistical significance was 








3.0 WORKING HYPOTHESIS AND RATIONALE  
Immune checkpoint inhibitor therapies have shown great results in the 
treatment of malignant melanoma and lung cancer. However, immune 
suppressive cells such as Th17 cells, TAMS and MDSCs attenuate effective anti-
tumor responses in many patients. MDSCs provide an important therapeutic 
target as they are responsible for T cell tolerance, angiogenesis and increased 
risk of metastasis. 
Targeting of MDSCs has been very challenging especially due to lack of a 
unique marker and plasticity of MDSCs. Despite these limitations, numerous 
studies have demonstrated the varying degree of efficacy of different agents in 
modulating MDSC suppressive phenotype. Based on recent studies, it has been 
identified that HIF-1α is important for MDSC differentiation and function (11). In 
addition, it has been reported that monocytic MDSCs upregulate glycolysis for 
their metabolic and biosynthetic needs (72). These data provide substantial 
evidence that glucose metabolism in monocytic MDSCs can be targeted to 
modulate their immune suppression and improve anti-tumor responses. 
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We believe that MDSCs upregulate the expression of 6-phosphofructo-2-
kinase/fructose-2,6-biphosphatase 3 (PFKFB3), and ultimately glycolysis (Fig. 8). 
This maintains a functional phenotype of MDSCs that suppress CD4 and CD8 T 
cell responses and result in poor anti-tumor responses (Fig. 8). We hypothesize 
that PFKFB3 blockade with small molecule inhibitor PFK-158 can modulate 
immune suppressive phenotype of MDSCs and result in improved anti-tumor 










Figure 8. MDSCs upregulate the expression of PFKFB3 that results in an 
increased rate of glycolysis. This maintains a functional phenotype of MDSCs 






Figure 9. PFKFB3 inhibition will result in reduced MDSC mediated CD4 and 











4.0 RESULTS – MOUSE STUDIES 
4.1 Both MDSC subsets, PMN- and M-MDSC expand in the spleens of 
tumor-bearing mice 
In order to study the functional characteristics of MDSCs – both PMN- and 
M-MDSCs and perform mechanistic studies, C57BL/6 WT mice were 
subcutaneously injected with B16-F10 melanoma cells (1 × 105 cells per mouse) 
in their left flanks. Spleens from tumor-bearing mice were harvested at 18-21 
days or when the tumor diameter reached 15-18 mm in size (Fig. 10). We then 
assessed and compared the frequency of both MDSC subsets in the spleens of 
naïve and tumor-bearing mice. Both MDSC subsets differentially expanded in the 
spleens of tumor-bearing mice compared with naïve mice (Fig. 11). Murine PMN-
MDSCs are defined as SSChighCD45posCD11bposLy6-Gpos and M-MDSCs are 




Figure 10. Schematic representation of the steps involved in the sorting of 
PMN- and M-MDSCs from the spleens of B16-F10 tumor bearing mice. Six-
eight week old male C57BL/6 WT mice were injected subcutaneously with 1 × 
105 B16-F10 melanoma cells. After 18 days or when the tumor diameter reached 
15-18 mm in size, spleens from these tumor bearing mice were harvested. PMN- 
and M-MDSCs were sorted using mouse MDSC isolation kit as per 






Figure 11. MDSC subsets differentially expanded in the spleens of tumor-
bearing mice compared with naïve mice. C57BL/6 WT mice were 
subcutaneously implanted with B16-F10 melanoma (1 × 105 cells per mouse) 
and spleens were harvested at day 18 or when the tumor diameter reached 15-
18 mm in size. Representative dot plots of the frequencies of PMN- 
(SSChighCD11bposLy6-Gpos) and M-MDSCs (SSClowCd11bposLy6-Cpos) in naïve 







4.2 PFKFB3 is over-expressed in splenic M-MDSCs from B16-F10 tumor 
bearing mice 
Western blot was performed to determine the expression of PFKFB3 in 
both MDSC subsets from both naïve and tumor-bearing mice. We found that 
PFKFB3 is significantly over-expressed in M-MDSCs sorted from the spleens of 
B16-F10 tumor-bearing mice compared with M-MDSCs sorted from the spleens 
of naïve mice (Fig. 12A and B). However, in PMN-MDSCs there was no 










Figure 12. PFKFB3 is over-expressed in splenic M-MDSCs from tumor-
bearing mice. PMN- and M-MDSCs were sorted from the spleens of naïve and 
B16-F10 tumor-bearing mice using magnetic bead sorting as per manufacturer’s 
protocol (Fig. 9). Using western blot, expression of PFKFB3 was determined in 
(A) M- and (C) PMN-MDSCs from the spleens of naïve and B16-F10 tumor-
bearing mice. (B) Representative bar graph of relative expression of PFKFB3 in 
M-MDSCs from naïve and B16-F10 tumor bearing mice determined using 







4.3 PFKFB3 inhibition with PFK-158 reduces M-MDSC suppressive activity 
MDSCs circulating in the peripheral blood or in the peripheral lymphoid 
organs such as spleen result in antigen specific T cell suppression. To this end, 
we first wanted to determine if PMN- or M-MDSCs sorted from the spleens of 
B16-F10 tumor-bearing mice suppressed OVA-specific T cell proliferation. Next, 
we wanted to determine if PFKFB3 inhibition with PFK-158 resulted in reduced 
MDSC antigen specific T cell suppression (Fig. 13). M-MDSCs sorted from the 
spleens of B16-F10 tumor-bearing mice suppressed OVA-specific T cell 
proliferation and this suppression was significantly reduced following PFKFB3 
inhibition with PFK-158 (Fig. 14). However, PMN-MDSCs did not suppress OVA-
specific T cell proliferation and the functional profile of these cells did not change 
following PFKFB3 inhibition with PFK-158 (Fig. 15). This provides evidence that 
in B16-F10 melanoma model, M- and not PMN-MDSCs are suppressive. 
Furthermore, M-MDSCs express high PFKFB3 and inhibition with PFK-158 





Figure 13. Schematic representation of the steps involved in set-up of 
functional assay using splenic MDSCs. PMN- and M-MDSCs from the spleens 
of B16-F10 tumor-bearing mice were sorted using magnetic bead separation as 
per manufacturer’s protocol. MDSCs were then cultured overnight with vehicle 
control or PFK-158 (5 µM). The following day, cells were washed and plated with 
OT-II splenocytes in a 96-well flat-bottom plate in different ratios for 72 hours in 
the presence of ovalbumin (200 µg/ml). Cells were pulsed with [3H]-thymidine 
12-16 hours before harvesting. Uptake of [3H]-thymidine was measured using 
scintillation reader and percent splenocyte inhibition was calculated to evaluate 





Figure 14. PFKFB3 inhibition with PFK-158 reduces M-MDSC suppressive 
activity. M-MDSCs pretreated with vehicle control and PFK-158 (5 µM) were co-
cultured with OT-II splenocytes in the presence of ovalbumin (200 µg/mL) for 72 
hours at 1:2, 1:4 and 1:8 ratio. Percent splenocyte inhibition was calculated. Line 
graph of percent splenocyte inhibition following treatment of splenic M-MDSCs 
with vehicle control and PFK-158. Results are representative of three 






Figure 15. Splenic PMN-MDSCs do not suppress T cell activity in B16-F10 
tumor model. PMN-MDSCs pretreated with vehicle control and PFK-158 (5 µM) 
were co-cultured with OT-II splenocytes in the presence of ovalbumin (200 
µg/mL) for 72 hours at 1:2, 1:4 and 1:8 ratio. Percent splenocyte inhibition was 
calculated. Line graph of percent splenocyte inhibition following treatment of 
splenic PMN-MDSCs with vehicle control and PFK-158. Results are 






4.4 PFKFB3 inhibition with PFK-158 reduces markers of suppression in 
splenic M-MDSCs 
Arginase 1 and iNOS are important markers of suppression in monocytic 
MDSCs. We have clearly demonstrated that PFKFB3 is over-expressed in 
monocytic MDSCs from the spleens of B16-F10 tumor bearing mice and its 
inhibition reduces M-MDSC suppressive activity (Fig. 12A and 14). In order to 
determine the mechanistic link for reduced M-MDSC suppressive activity 
following PFKFB3 inhibition with PFK-158, we first determined baseline 
expression of arginase 1 and iNOS mRNA in naïve and tumor-bearing mice. Both 
arginase 1 and iNOS were highly expressed in splenic M-MDSCs from tumor-
bearing mice compared to naïve mice (Fig, 16A and 17A). Then we sought to 
evaluate the expression of arginase 1 and iNOS mRNA following treatment with 
vehicle control and PFK-158. Both arginase 1 and iNOS mRNA expression 
decreased significantly following treatment with PFK-158 compared to treatment 
with vehicle control (Fig. 16B and 17B). Using arginase activity assay, we saw a 
significant decrease in arginase activity following PFKFB3 inhibition with PFK-
158 both with and without the addition of lipopolysaccharide (LPS) (Fig. 16C). 
Splenic M-MDSCs did not produce NO without LPS stimulation. However, LPS 
stimulation resulted in the production of NO which was completely abrogated 
following PFKFB3 inhibition with PFK-158 (Fig. 17C).      
PFKFB3 inhibition with PFK-158 reduced splenic M-MDSC suppressive 
activity and markers of suppression such as arginase and iNOS. Next, we sought 
to determine if treatment with PFK-158 resulted in phenotypic change in the M-
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MDSCs. On flow cytometry, no change in the frequency or phenotype of splenic 
M-MDSCs was noted following treatment with vehicle control and PFK-158 (Fig. 
18). This provides evidence that PFKFB3 inhibition results in reduced 
suppressive activity primarily through decreased expression of arginase 1 and 
iNOS, and not through the induction of phenotypic change in these cells to 








Figure 16. PFKFB3 maintains arginase expression in splenic M-MDSCs 
from B16-F10 tumor-bearing mice. (A) qRT-PCR analysis of arginase 1 mRNA 
expression in fresh M-MDSCs sorted from the spleens of naïve (n=3) and tumor-
bearing mice (n=3). (B) Arginase 1 mRNA expression was determined in splenic 
M-MDSCs following treatment with vehicle control (n=4) and PFK-158 (5 µM) 
(n=4). (C) Arginase activity was determined following treatment with vehicle 
control (n=4) and PFK-158 (5 µM) (n=4) both with and without the addition of 
lipopolysaccharide (LPS, 200 ng/mL). Results are representative of three 




Figure 17. PFKFB3 maintains iNOS expression in splenic M-MDSCs from 
B16-F10 tumor-bearing mice. (A) qRT-PCR analysis of iNOS mRNA 
expression in fresh M-MDSCs sorted from the spleens of naïve (n=3) and B16-
F10 tumor-bearing mice (n=3). (B) iNOS expression in splenic M-MDSCs 
following treatment with vehicle control (n=4) and PFK-158 (5 µM) (n=4). (C) NO 
production was determined following treatment with vehicle control (n=4) and 
PFK-158 (n=4) both with and without the addition of LPS (200 ng/mL). Results 





Figure 18. Phenotype of splenic M-MDSCs from B16-F10 tumor-bearing 
mice does not change following PFKFB3 inhibition with PFK-158 (5 µM). 
Representative contour plots of (A) splenic M-MDSCs treated with vehicle control 








4.5 Bone-marrow derived MDSCs express high PFKFB3 
Sorting of tumor MDSCs using magnetic bead separation has limitations 
especially with significant tumor cell contamination. In order to overcome this 
limitation and study the functional and mechanistic characteristics of tumor 
MDSCs, we used bone marrow MDSC model as described by Marigo et al (Fig. 
19) (14). Bone marrow cells from C57L/B6 WT mice are cultured in the presence 
of GM-CSF and IL6 for four days. MDSCs induced subsequently provide an ex-
vivo correlate of tumor MDSCs. 
We first sought to determine if bone marrow-derived MDSCs using this 
model has high expression of PFKFB3. Western blot analysis showed that bone 
marrow cells cultured in the presence of GM-CSF and IL6 expressed high 
PFKFB3 compared with fresh bone marrow cells and bone marrow cells cultured 
in the presence of GM-CSF alone (Fig. 20A and B). On flow cytometry, the 
frequency of CD11bposGR1pos cells increases significantly when fresh bone 
marrow cells are cultured in the presence of GM-CSF and IL6 (Fig. 20C). 
 







Figure 19. Schematic representation of the steps involved in the induction 
of bone marrow-derived MDSCs. Bone marrow cells obtained from the tibias 
and fibulas of C57BL/6 WT mice were cultured in the presence of GM-CSF (40 
ng/mL) and IL6 (40 ng/mL) for four days. MDSCs obtained subsequently provide 






Figure 20. PFKFB3 is over-expressed in bone marrow-derived MDSCs (BM-
MDSC). Bone marrow cells from C57BL/6 WT mice were cultured in the 
presence of GM-CSF (40 ng/mL) and IL6 (40 ng/mL) for four days. (A) western 
blot and (B) bar graph of relative expression of PFKFB3 in BM-MDSC compared 
with fresh bone marrow cells and bone marrow cells cultured in the presence of 
GM-CSF alone. (C) Representative greyscale density plot of fresh bone marrow 
cells and BM-MDSCs (CD11bposGR1pos). Results are representative of three 
independent experiments.  
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4.6 PFKFB3 inhibition with PFK-158 reverses bone marrow-derived MDSCs 
suppressive activity 
Next, we sought to determine if bone marrow-derived MDSCs were 
suppressive and if suppressive activity can be reversed following PFKFB3 
inhibition with PFK-158. Bone marrow cells obtained from C57BL/6 WT mice 
were cultured in the presence of GM-CSF and IL6 for four days. PFK-158 at 5 
µM dose or vehicle control (DMSO) was added to the cultures on day zero and 
then 2.5 µM dose or vehicle control was added again on day three. On day four, 
cells were harvested and then co-cultured with OT-II splenocytes in different 
rations in a 96-well flat-bottom plate in the presence of ovalbumin for 72 hours. 
12-16 hours before harvesting the plates, cells were pulsed with [3H]-thymidine 
and percent splenocyte inhibition was calculated (Fig. 21). We found that the 
bone marrow-derived MDSCs suppressed the T cell proliferation which was 
reversed following PFKFB3 inhibition with PFK-158 at all the ratios that were 
tested (Fig. 22).  









Figure 21. Schematic representation of the steps involved in functional 
assay with BM-MDSC. PFK-158 (5 µM) or vehicle control was added on day 
zero and then again on day three (PFK-158, 2.5 µM) to the bone marrow cells 
co-cultured with GM-CSF and IL6. On day four, cells were harvested, washed 
and then plated with OT-II splenocytes in a 96-well flat-bottom plate in different 
ratios for 72 hours in the presence of ovalbumin. Cells were pulsed with [3H]-
thymidine 12-16 hours before harvesting. Incorporation of [3H]-thymidine was 
measured using scintillation reader and percent splenocyte inhibition was 
calculated to evaluate the difference in suppressive activity of BM-MDSCs 




Figure 22. PFKFB3 inhibition with PFK-158 reduces bone marrow-derived 
MDSC suppressive activity. Bone marrow-derived MDSCs treated with vehicle 
control and PFK-158 were co-cultured with OT-II splenocytes in the presence of 
ovalbumin at 1:4, 1:8 and 1:16 ratios. Line graph showing the suppressive 
activity of vehicle control and PFK-158 treated bone marrow-derived MDSCs. 







4.7 PFKFB3 inhibition reduces markers of suppression in bone marrow-
derived MDSCs  
Bone marrow-derived MDSCs suppress T cell proliferation primarily 
through the upregulation of arginase 1 expression and NO production. Inhibition 
of PFKFB3 during the induction of bone marrow-derived MDSCs resulted in 
complete loss of arginase 1 expression on western blot and reduced activity on 
arginase assay (Fig. 23A and B). We also sought to analyze if NADPH-oxidase 
(NOX)/ROS pathway contributed to immune suppressive phenotype of these 
cells. On western blot analysis, there was no difference in the expression of 
NOX2 and NOX4 enzymes between the vehicle control and PFK-158 treated 
BM-MDSCs (Fig. 23A). Similarly, on flow cytometry analysis, there was no 
detectable difference noted in DCF-detectable ROS between the two (Fig. 24B).  
We also assessed NO production using Griess assay both during 
induction and following differentiation of BM-MDSCs. To evaluate the NO 
production during the induction process, PFK-158 was added as described 
previously, on day zero and then on day three. In the post-differentiation 
condition, bone marrow cells were cultured with GM-CSF and IL6 for four days 
and then treated with vehicle control or PFK-158 for 16-18 hours. NO production 
was stimulated by the addition of LPS. Supernatants from these conditions were 
used to determine NO level as per manufacturer’s protocol. PFKFB3 inhibition 
with PFK-158 both during induction and post differentiation resulted in 
significantly reduced production of NO compared with control (Fig. 24A).  
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We next performed flow cytometry analysis of bone marrow-derived 
MDSCs following treatment with vehicle control and PFK-158 to assess if 
PFKFB3 inhibition resulted in phenotypic transformation of these cells to APCs. 
No change in the phenotype of these cells was seen with or without treatment 
with PFK-158 (Fig. 25 B and C). These experiments provide further evidence 
that PFK-158 modulates immune suppressive phenotype of bone marrow-
derived MDSCs through reduced arginase 1 expression and NO production, and 
not through ROS or through induction of phenotypic change. 
 













Figure 23. PFKFB3 maintains arginase 1 expression in BM-MDSCs. (A) 
Western blot analysis of arginase 1, NOX2 and NOX4 expression relative to 
beta-actin in vehicle control and PFK-158 treated bone marrow-derived MDSCs. 
(B) Arginase activity was assessed using QuantichromTM arginase assay – Darg 
100 as per manufacturer’s protocol. Bar graph of arginase activity between the 
vehicle control and PFK-158 treated groups. Results are representative of three 









Figure 24. PFKFB3 maintains NO production in BM-MDSCs. (A) NO 
production was stimulated using LPS. Using Griess assay, NO production was 
determined in the supernatants from the vehicle control treated group and bone 
marrow-derived MDSC groups treated with PFK-158 during induction and post-
differentiation. (B) DCF-detectable ROS levels in bone marrow-derived MDSCs 
treated with vehicle control and PFK-158 (5 µM). Results are representative of 




















Figure 25. PFKFB3 inhibition does not change phenotype of BM-MDSCs. 
(A-C) Flow cytometry analysis of fresh bone marrow cells, BM-MDSCs and BM-
MDSCs + PFK-158. Representative contour plots of (A) fresh bone marrow cells 
(B) BM-MDSCs (C) BM-MDSCs following PFKFB3 inhibition with PFK-158.  
Bone marrow-derived PMN or G-MDSCs are SSChighCD11bposGR1high and M-











4.8 Bone marrow-derived monocytic MDSCs express high PFKFB3 and 
cause antigen non-specific T cell suppression 
 Tumor MDSCs result in antigen non-specific T cell suppression. Bone 
marrow derived MDSCs provide an ex-vivo model to study tumor MDSCs. To this 
end, we then sought to determine the functional and mechanistic characteristics 
of monocytic subset sorted from bone marrow-derived MDSCS. Bone marrow 
cells from C57BL/6 WT mice were cultured with GM-CSF and IL6 for four days 
(14). At the end of four day culture, monocytic and granulocytic subsets were 
sorted using mouse MDSC isolation kit as per manufacturer’s protocol (Miltenyi 
Biotec) (Fig. 26). We first assessed the expression of PFKFB3 in the monocytic 
subset. Using western blot analysis, bone marrow-derived M-MDSCs had high 
expression of PFKFB3 compared with fresh bone marrow cells (Fig. 27).  
In order to study the suppressive function, both granulocytic and 
monocytic subsets were then treated with vehicle control and PFK-158 (5 µM) for 
16-18 hours. The following day, cells were harvested, washed and co-cultured 
with CFSE labeled splenocytes from WT mice in an anti-CD3 coated 96-well flat-
bottom plate in the presence of anti-CD28 in different ratios for 72 hours. Cells 
were then stained for CD4 and CD8, and T cell proliferation was determined 
using flow cytometry (Fig. 26). M-MDSC induced suppression was more 
impressive for CD4 compared to CD8 T cells (Fig. 28 and 29). Furthermore, 
PFKFB3 inhibition with PFK-158 resulted in reduced the suppressive activity of 
the M-MDSC subset (Fig. 28 and 29) while there was no change in the 




Figure 26. Schematic representation of the steps involved in the generation 
and sorting bone marrow-derived M-MDSCs and functional assay. Fresh 
bone marrow cells were cultured in the presence of GM-CSF (40 ng/mL) and IL6 
(40 ng/mL) for four days (14). Following the manufacturer’s protocol, monocytic 
and polymorphonuclear subsets were sorted using magnetic bead separation 
(Miltneyi Biotec). Sorted cells were cultured with vehicle control or PFK-158 (5 
µM) for 16-18 hours. The following day, cells were washed and co-cultured with 
CFSE labeled splenocytes from WT mice in an anti-CD3 coated flat-bottom 96-
well plate in the presence of anti-CD28 for 72 hours. Cells were then harvested 
and stained for CD4 and CD8. Flow cytometry was then performed to determine 





Figure 27. PFKFB3 is over-expressed in bone marrow-derived M-MDSCs. 
Representative western blot of PFKFB3 expression in bone marrow-derived M-
















Figure 28. PFKFB3 inhibition with PFK-158 reverses bone marrow-derived 
M-MDSC suppression on CD4 T cell proliferation. Bone marrow-derived M-
MDSCs were cultured with CFSE-labeled splenocytes in anti-CD3 coated 96-well 
flat bottom plate in the presence of anti-CD28 beads for three days. Splenocytes 
were then stained for CD4 and activation was determined. Representative (A) 
histograms and (B) bar graphs showing the percentage of proliferated 










Figure 29. PFKFB3 inhibition with PFK-158 reverses bone marrow-derived 
M-MDSC suppression on CD8 T cell proliferation. (A and B) Bone marrow-
derived M-MDSCs were cultured with CFSE-labeled splenocytes in anti-CD3 
coated 96-well flat bottom plate in the presence of anti-CD28 beads for three 
days. Splenocytes were then stained for CD8 and activation was determined. 
Representative (A) histograms and (B) bar graphs showing the percentage of 










Figure 30. Bone marrow-derived PMN-MDSCs do not suppress CD4 T cell 
proliferation. Line graph for splenocytes showing the percentage of proliferated 








Figure 31. Bone marrow-derived PMN-MDSCs do not suppress CD8 T cell 
proliferation. Line graph for splenocytes showing the percentage of proliferated 









4.9 PFKFB3 inhibition reduces arginase 1 expression and activity in bone 
marrow-derived M-MDSCs 
Tumor MDSCs result in antigen non-specific T cell suppression through 
dramatic upregulation of arginase 1 and iNOS. We showed that bone marrow-
derived M-MDSCs suppress T cell function in an antigen independent manner. 
To study the mechanistic basis for reduced bone marrow-derived M-MDSC 
induced T cell suppression following PFKFB3 inhibition, we determined the 
change in arginase 1 activity. We found that following PFKFB3 inhibition with 
PFK-158, arginase 1 mRNA expression (Fig. 32A) and arginase activity 
decreased significantly compared with vehicle control (Fig. 32 B). Bone marrow-
derived M-MDSCs did not produce NO even after LPS stimulation (Fig. 32C). 
These experiments provide evidence that bone marrow-derived M-MDSCs result 
in antigen non-specific T cell suppression primarily through upregulation of 
arginase expression and activity. And, PFKFB3 inhibition with PFK-158 reduces 







Figure 32. PFKFB3 maintains arginase 1 activity in bone marrow-derived M-
MDSCs. (A) Bar graphs showing qRT-PCR analysis of arginase 1 mRNA 
expression, (B) QuantichromTM arginase assay showing arginase activity in bone 
marrow-derived M-MDSCs following treatment with vehicle control and PFK-158, 
and (C) Griess assay showing NO production in whole BM-MDSCs and bone 
marrow-derived M-MDSCs following LPS stimulation. Results are representative 
of three independent experiments. *p≤0.05, **p≤0.005. 
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4.10 Bone marrow-derived MDSCs upregulate glycolysis 
Next we sought to study the metabolic profile of MDSCs. To this end, we 
used the Seahorse® platform which analyzes the extracellular acidification rate 
(ECAR), an index for glycolysis and oxygen consumption rate (OCR) which 
provides a measure for mitochondrial activity or oxidative phosphorylation. Bone 
marrow-derived MDSCs were obtained following culture of bone marrow cells 
with GM-CSF and IL6 as described previously. In addition, fresh bone marrow 
cells were harvested from WT mice. Using the Seahorse® platform, we 
measured the ECAR and OCR for fresh bone marrow cells and bone marrow-
derived MDSCs. We found that the bone marrow-derived MDSCs had higher 
ECAR and OCR compared with fresh bone marrow cells (Fig. 33 A and B).  
Taking in to account PFKFB3 over-expression in bone marrow-derived M-
MDSCs compared with fresh bone marrow cells (Fig. 27), we sought to 
determine the effect of PFKFB3 inhibition on ECAR and OCR in these cells. 
Bone marrow-derived M-MDSCs were sorted using magnetic bead separation as 
described previously and then treated with vehicle control and PFK-158 for 16-18 
hours. Bioenergetic profile of these cells was then analyzed using the 
Seahorse®. Following PFKFB3 inhibition, both ECAR and OCR decreased 
significantly compared with vehicle control (Fig. 33 C and D). These data 
demonstrate that MDSCs upregulate glycolysis which is the result of higher 





Figure 33. PFKFB3 maintains high rate of glycolysis in BM-MDSCs. Bar 
graphs of (A) ECAR and (B) OCR in fresh bone marrow cells and bone marrow-
derived MDSCS, (C) ECAR and (D) OCR comparing bone marrow-derived M-
MDSCs following treatment with vehicle control and PFK-158. Results are 
representative of three independent experiments. ***p≤0.0005. 
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4.11 HIF-1α expression correlates with the expression of PFKFB3 in M-
MDSCs in hypoxic culture conditions 
HIF-1α has been shown to play an important role in MDSC function and 
differentiation (11). We then sought to determine the relationship between the 
expression of HIF-1α and PFKFB3 in monocytic MDSCs. Splenic M-MDSCs from 
B16-F10 tumor-bearing mice were sorted as described previously using magnetic 
bead separation (Miltneyi Biotec). M-MDSCs were then cultured in 25% B16-F10 
tumor cell conditioned media (TCCM) under hypoxic (1% O2) and normoxic 
conditions for 24 and 48 hours (Fig. 34). Western blot analysis was then 
performed to evaluate the expression of HIF-1α and PFKFB3 under these 
conditions. HIF-1α expression was upregulated at 24 hours which correlated with 
a higher expression of PFKFB3 under hypoxia relative to the expression under 
normoxia (Fig. 35). At 48 hours, expression of HIF-1α and PFKFB3 was still high 
under hypoxia compared to normoxia (Fig. 35). These results clearly 
demonstrate that HIF-1α expression correlates with the expression of PFKFB3 in 









Figure 34. Schematic representation of the steps involved in the culture of 
splenic M-MDSCs under hypoxia. M-MDSC sorted from the spleens of B16-
F10 tumor bearing mice were cultured in 25% B16-F10 tumor cell conditioned 











Figure 35. Hypoxia inducible factor 1α (HIF-1α) expression correlates with 
the expression of PFKFB3 under hypoxic conditions. Representative western 
blot of HIF-1α and PFKFB3 in splenic M-MDSCs cultured in 25% B16-F10 tumor 
cell conditioned media (TCCM) under normoxia and hypoxia (1% O2) at 24 and 












4.12 M-MDSCs under hypoxia result in antigen non-specific T cell 
suppression  
In the hypoxic tumor microenvironment (TME), MDSCs have been shown 
to cause antigen non-specific T cell suppression (11). MDSCs isolated from HIF-
1α knockout mice resulted in less antigen non-specific T cell suppression 
compared with HIF-1α WT mice (11). In order to study the differential functional 
characteristics of splenic M-MDSCs under hypoxia, cells were cultured in 25% 
B16-F10 TCCM under normoxia and hypoxia for 48 hours. M-MDSCs were then 
co-cultured with CFSE labeled splenocytes from WT mice in an anti-CD3 coated 
96-well flat-bottom plate in the presence of anti-CD28 for 72 hours. Cells were 
then stained for CD4 and CD8, and T cell proliferation was measured using flow 
cytometry (Fig. 36). Our results show that MDSCs cultured under hypoxic 
conditions result in antigen non-specific suppression of CD4 and CD8 T cell 
proliferation (Fig. 37 and 38). However, MDSCs cultured under normoxia failed 
to cause substantial antigen non-specific T cell suppression (Fig. 37 and 38). 
These findings clearly demonstrate that M-MDSCs under hypoxia upregulate the 
expression of HIF-1α which then upregulates the expression of PFKFB3 and 
increases the rate of anaerobic glycolysis, and results in a functional phenotype 
of M-MDSCs which suppress T cell activity in an antigen non-specific manner. 
The experiment was not repeated as it was done to demonstrate the induction of 





Figure 36. Schematic representation of the steps involved in set-up of 
functional assay for splenic M-MDSCs cultured under normoxia and 
hypoxia. M-MDSC sorted from the spleens of B16-F10 tumor bearing mice were 
cultured in 25% B16-F10 tumor cell conditioned media (TCCM) under normoxia 
or hypoxia for 48 hours. Cells were then co-cultured with CFSE labeled 
splenocytes from WT mice in anti-CD3 coated flat-bottom 96-well plate in the 
presence of anti-CD28 for 72 hours. Cells were then stained for CD4 and CD8 to 






Figure 37. Splenic M-MDSCs cultured under hypoxic conditions result in 
antigen non-specific suppression of CD4 T cells. (A and B) Splenic M-
MDSCs were cultured under normoxia and hypoxia as described above in the 
schematic representation. Subsequently, M-MDSCs were co-cultured with CFSE-
labeled splenocytes in anti-CD3 coated 96-well flat-bottom plate in the presence 
of anti-CD28 beads for three days. Splenocytes were then stained for CD4 and 
activation was determined. Representative (A) histograms and (B) bar graphs 








Figure 38. Splenic M-MDSCs cultured under hypoxic conditions result in 
antigen non-specific suppression of CD8 T cells. (A and B) Splenic M-
MDSCs were cultured under normoxia and hypoxia as described above in the 
schematic representation. Subsequently, M-MDSCs were co-cultured with CFSE-
labeled splenocytes in anti-CD3 coated 96-well flat-bottom plate in the presence 
of anti-CD28 beads for three days. Splenocytes were then stained for CD8 and 
activation was determined. Representative (A) histograms and (B) bar graphs 








4.13 PFKFB3 inhibition reduces M-MDSC-mediated antigen non-specific 
suppressive activity under hypoxic culture conditions 
Next we wanted to determine if PFKFB3 inhibition resulted in reduced M-
MDSC antigen non-specific suppressive activity under hypoxia. Splenic M-
MDSCs from B16-F10 tumor-bearing mice were sorted as described previously 
using magnetic bead separation (Miltenyi Biotec). M-MDSCs were then cultured 
in 25% B16-F10 TCCM under 1% O2 for 48 hours with vehicle control and PFK-
158 (5 µM). At the end of 48 hours, cells were harvested, washed and co-
cultured with CFSE labeled splenocytes from C57BL/6 WT mice in different ratios 
in an anti-CD3 coated 96-well plate in the presence of anti-CD28 for 72 hours. 
Cells were then harvested and stained for CD4 and CD8, and T cell proliferation 
was determined using flow cytometry (Fig. 39). PFKFB3 inhibition with PFK-158 
resulted in reduced M-MDSC antigen non-specific CD4 and CD8 T cell 
suppression under hypoxia (Fig. 40 and 41). Again, M-MDSC suppression was 
more pronounced for CD4 compared to CD8 T cells (Fig. 40 and 41). These data 
provide further evidence that PFKFB3 inhibition can modulate M-MDSC 
suppression and improve T cell proliferation.  
Similar to our previous experiments, we wanted to determine if hypoxic 
conditions and PFKFB3 inhibition resulted in the change of phenotype. At 48 
hours, there was no difference in the frequency and phenotype of splenic M-
MDSCs cultured under normoxia, hypoxia with vehicle control and hypoxia with 
PFK-158 (Fig. 42). The percentage of GR1pos population decreases when cells 




Figure 39. Schematic representation of the steps involved in set-up of 
functional assay with splenic M-MDSCs under hypoxia with or without PFK-
158. M-MDSC sorted from the spleens of B16-F10 tumor bearing mice were 
cultured in 25% B16-F10 tumor cell conditioned media (TCCM) under hypoxia for 
48 hours with vehicle control and PFK-158 (5 µM). Cells were harvested and 
washed after 48 hours, and then co-cultured with CFSE labeled splenocytes from 
WT mice in an anti-CD3 coated flat-bottom 96-well plate in the presence of anti-
CD28 for 72 hours. Cells were then stained for CD4 and CD8 to determine 





Figure 40. PFKFB3 inhibition reduces M-MDSC antigen non-specific 
suppressive activity for CD 4 T cells under hypoxic conditions. (A and B) 
Splenic M-MDSCs were cultured under hypoxia with vehicle control and PFK-158 
as described above in the schematic representation. Subsequently, M-MDSCs 
were co-cultured with CFSE-labeled splenocytes in anti-CD3 coated 96-well flat-
bottom plate in the presence of anti-CD28 beads for three days. Splenocytes 
were then stained for CD4 and activation was determined. Representative (A) 
histograms and (B) bar graphs showing the percentage of proliferated 








Figure 41. PFKFB3 inhibition reduces M-MDSC antigen non-specific 
suppressive activity for CD 8 T cells under hypoxic conditions. (A and B) 
Splenic M-MDSCs were cultured under hypoxia with or without PFK-158 as 
described above in the schematic representation. Subsequently, M-MDSCs were 
co-cultured with CFSE-labeled splenocytes in anti-CD3 coated 96-well flat-
bottom plate in the presence of anti-CD28 beads for three days. Splenocytes 
were then stained for CD8 and activation was determined. Representative (A) 
histograms and (B) bar graphs showing the percentage of proliferated 







Figure 42. PFKFB3 inhibition does not change phenotype of splenic M-
MDSCs under hypoxic conditions. Representative contour plot (A) splenic M-
MDSC under normoxia, under hypoxia for 48 hours with (B) vehicle control, and 



























4.14 PFK-158 reduces M-MDSC suppressive activity in vivo 
In order to evaluate the efficacy of PFKFB3 inhibition on M-MDSC 
suppressive function, B16-F10 tumor bearing C57BL/6 WT mice were injected 
intra-peritoneally with PFK-158. Mice were randomized to vehicle control 
(DMSO) or PFK-158 groups. When the tumor volume reached approximately 100 
mm3, they were injected with DMSO and PFK-158 intraperitoneally on days 11, 
13, 16 and 18. Tumor volumes were measured on the days of injections. On day 
19, spleens from mice in the both groups were harvested. M-MDSCs were sorted 
as described previously using magnetic bead sorting (Miltneyi Biotec). Equal 
number of splenic M-MDSCs from both groups were co-cultured with CFSE 
labeled OT-II splenocytes in the presence of ovalbumin in flat-bottom 96-well 
plate for 72 hours. Cells were then stained for CD4 and T cell proliferation was 
measured using flow cytometry. PFKFB3 inhibition with PFK-158 was associated 
with decrease in tumor volumes compared to the control (Fig. 43A). Also, splenic 
M-MDSCs from PFK-158 treated mice were less suppressive to CD4 T cell 
function compared to the vehicle control treated mice (Fig. 43B).  
Further, we sought to evaluate the effect of in vivo PFKFB3 inhibition on 
markers of suppression in splenic M-MDSCs. Using qRT-PCR, splenic M-
MDSCs isolated from PFK-158 treated mice had lower expression of arginase 1 
mRNA compared with vehicle control treated mice (Fig. 44A). Also, splenic M-
MDSCs from tumor bearing mice treated with vehicle control had significantly 
higher arginase activity compared with naïve mice (Fig. 44B). This high arginase 
activity in tumor bearing mice decreased significantly following treatment with 
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PFK-158 (Fig. 44B). In addition, we analyzed the expression of iNOS by qRT-
PCR in vehicle control and PFK-158 treated tumor-bearing mice. Treatment with 
PFK-158 resulted in reduced expression of iNOS mRNA compared to treatment 
with vehicle control (Fig. 44C).  
Next, we wanted to assess phenotypic changes in different immune cell 
populations in tumor-bearing mice with and without treatment with PFK-158. 
Interestingly, following treatment with PFK-158 monocytic MDSC 
(SSClowCD11bposGR1low) population decreased compared with vehicle control 
treated mice (Fig. 45). However, PFKFB3 inhibition did not have any effect on 
the frequencies of PMN-MDSCs (SSChighCD11bposGR1high) between vehicle 
control and PFK-158 treated mice (Fig. 45). There was also no change in the 
frequencies of macrophages (CD11bposF4/80pos) seen following treatment with 
PFK-158 (Fig. 46A); however, there was an increase in the population of DCs 
(CD11bposCD11cpos) (Fig. 46B). 
These data combined, provide substantial evidence that PFKFB3 
inhibition in vivo not only reduces splenic M-MDSC suppressive activity through 
reduced expression of suppressive markers such as arginase 1 and iNOS but 




Figure 43. In vivo PFKFB3 inhibition reduces tumor volume and M-MDSC 
suppressive function. C57BL/6 WT mice were randomized to vehicle control 
and PFK-158 treatment (n = four per group). Mice were injected with vehicle 
control (DMSO) and PFK-158 when tumor volumes on average reached 100 
mm3. DMSO and PFK-158 were administered intra-peritoneally on days 11, 13, 
16 and 18 for total of four injections. Tumor measurements were taken on the 
days of the injections using digital calipers and tumor volumes were calculated 
based on the formula=length × width2/2. On day 19, spleens from each group 
were harvested and M-MDSCs were isolated using magnetic bead separation as 
described previously. M-MDSCs were co-cultured with CFSE labelled OT-II 
splenocytes in the presence of ovalbumin and percent splenocyte proliferation 
was determined using flow cytometry. (A) Line graph of tumor volumes and (B) 
bar graph showing the percentage of proliferated CD4 T cells following intra-
peritoneal injections with DMSO and PFK-158. Results are representative of 





Figure 44. In vivo PFKFB3 inhibition reduces splenic M-MDSC suppressive 
markers. Representative bar graph showing results of (A) qRT-PCR for arginase 
1 mRNA expression in splenic M-MDSCs isolated from the spleens of tumor 
bearing mice injected with DMSO and PFK-158, (B) QuantichromTM arginase 
activity assay in splenic M-MDSCs from naïve mice, tumor bearing mice injected 
with vehicle control and PFK-158, and (C) qRT-PCR for iNOS expression in 
splenic M-MDSCs isolated from the spleens of tumor bearing mice injected with 
DMSO and PFK-158. Results are representative of three independent 
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Figure 45. In vivo PFKFB3 inhibition reduces the frequencies of splenic M-
MDSCs. Representative contour plots of splenic M-and PMN-MDSCs in (A) 



















Figure 46. In vivo PFKFB3 inhibition increases the frequencies of DCs. (A) 
Representative contour plots of (A) macrophages and (B) DCs in vehicle control 











4.15 PFKFB3 inhibition reduces lactic acid production in M-MDSCs 
One of the consequences of increased glycolytic flux is the increased 
production of lactic acid (32). Changes in the amount of lactic acid produced 
following PFKFB3 inhibition with PFK-158 was performed using a colorimetric 
lactate assay. Supernatants from M-MDSCs cultured in equal numbers treated 
with vehicle control and PFK-158 were collected and amount of lactic acid was 
measured as per manufacturer’s protocol. PFKFB3 inhibition resulted in 
significant decrease in lactic production in splenic M-MDSCs, whole BM-MDSCs 
and bone marrow-derived M-MDSCs compared to treatment with vehicle control 
(Fig. 47A, B and C). LDHA mRNA expression on qRT-PCR showed significant 




Figure 47. PFKFB3 maintains lactic acid production in M-MDSCs. 
Colorimetric lactate assay was performed to measure differences in lactic acid 
production between vehicle control and PFK-158 treated groups. Representative 
bar graphs for lactic acid production in (A) splenic M-MDSCs, (B) whole BM-
MDSCs and (C) bone marrow-derived M-MDSCs with and without treatment with 
PFK-158, and (D) qRT-PCR for LDHA mRNA expression in the splenic M-
MDSCs sorted from tumor-bearing mice injected with vehicle control or PFK-158. 


















































4.16 PFKFB3 inhibition reduces intracellular concentration of F-2,6-BP and 
glucose uptake 
To evaluate the efficiency of PFK-158 at inhibiting PFKFB3, intracellular 
levels of F-2,6-BP were determined using a previously described protocol. PFK-
158 at 5 µM dose significantly reduced intracellular levels of F-2,6-BP in the 
whole BM-MDSCs (Fig. 48A) and GR1pos BM-MDSCs (Fig. 48B). We also 
evaluated the efficiency of PFK-158 in reducing glucose uptake by MDSCs. In 
bone marrow-derived M-MDSCs, one hour treatment with PFK-158 resulted in 
reduced glucose uptake (Fig. 49). Together, these results provide evidence that 






Figure 48. PFK-158 reduces intracellular concentration of F-2,6-BP. 
Intracellular concentration of F-2,6-BP was measured as per previously 
described protocol. Representative bar graphs for F-2,6-BP levels with and 
without treatment with PFK-158 in (A) whole BM-MDSCs and (B) GR1pos BM-



























































Figure 49. PFK-158 reduces glucose uptake in bone marrow-derived M-
MDSCs. Glucose uptake by bone marrow-derived M-MDSCs was performed 
following one hour treatment with vehicle control and PFK-158. Cells were gated 
on FL1 channel. Representative bar graph and histogram for glucose uptake in 









5.0 RESULTS – HUMAN STUDIES 
5.1 PFKFB3 inhibition reduces circulating M-MDSC suppressive activity 
from late-stage melanoma patients 
We have now demonstrated that PFKFB3 inhibition reduces suppressive 
activity of M-MDSCs in mice. Next we wanted to determine if PFKFB3 inhibition 
resulted in reduced suppressive activity of circulating M-MDSCs from late-stage 
melanoma patients. Patients with late-stage melanoma presenting to the James 
Graham Brown Cancer Center at the University of Louisville who had been 
recently diagnosed and had not received any treatment in the prior six months 
were identified. Informed consent was obtained from the patients prior to the 
collection of peripheral blood as covered under University of Louisville IRB 
protocol number 08.0388. Peripheral blood from the patients was collected in 
CPT® tubes. Buffy coat was removed after centrifugation at 1600xg for 20 
minutes. Cells were washed and CD14pos MDSCs were isolated using magnetic 
bead separation as per manufacturer’s protocol (Miltneyi Biotec). M-MDSCs were 
then treated with vehicle control and PFK-158 for 16-18 hours. The following day, 
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cells were washed and co-cultured with CFSE labeled autologous T cells for four 
days. Flow cytometry was then performed to measure T cell proliferation (Fig. 
50). 
PFKFB3 inhibition with PFK-158 significantly reduced circulating M-MDSC 
suppression on T cell proliferation and increased IFN-γ secretion compared to 
vehicle control (Fig. 51 A-C). We also sought to determine the effect of PFKFB3 
inhibition on M-MDSC markers of suppression. qRT-PCR showed that circulating 
M-MDSCs from late-stage melanoma patients had high expression of iNOS 
mRNA compared with normal donors (Fig. 52A). And following treatment with 
PFK-158, the expression of iNOS mRNA was reduced significantly (Fig. 52B). 
Similarly on arginase assay, PFKFB3 inhibition with PFK-158 resulted in 
significant reduction in activity compared to vehicle control (Fig. 52C). No 
difference in frequency or the phenotype was noted following treatment with 











Figure 50. Schematic representation of the steps involved in isolating 
circulating M-MDSCs from late-stage melanoma patients. Patients with late-
stage melanoma presenting to the James Graham Brown Cancer Center 
(JGBCC) at the University of Louisville were identified for the study. Peripheral 
blood was collected in CPT® tubes by the staff of the JGBCC Biorepository and 
covered under University of Louisville IRB protocol number 08.0388. Following 
centrifugation at 1600xg, buffy coat was collected and CD14pos M-MDSCs were 
sorted using magnetic bead separation as per manufacturer’s protocol. M-
MDSCs were then treated with vehicle control and PFK-158 for 16-18 hours. 
Cells were washed and then co-cultured with CFSE labelled autologous T cells 







Figure 51. PFKFB3 inhibition reverses suppressive activity of circulating M-
MDSCs from late-stage melanoma patients. Melanoma patient-derived 
CD14pos MDSCs (n=7) were pretreated with vehicle control and PFK-158 (5 µM). 
M-MDSCs were then co-cultured with CFSE-labeled autologous T cells in the 
presence of anti-CD3/anti-CD28 beads for four days and T-cell activation was 
determined. Representative (A) histograms and (B) bar graphs showing the 







Figure 52. PFKFB3 inhibition decreases markers of suppression in 
circulating M-MDSCs from late-stage melanoma patients. Representative bar 
graphs showing results of (A) qRT-PCR analysis of iNOS mRNA expression in 
circulating CD14pos cells from normal donors (n=5) and late-stage melanoma 
patients (n=5), (B) iNOS mRNA expression (n=5) and (C) QuantichromTM 
arginase assay (n=2) showing arginase activity in circulating M-MDSCs following 
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Figure 53. PFKFB3 inhibition does not change frequency and phenotype of 
circulating M-MDSCs from late-stage melanoma patients. Representative 
contour plots of circulating M-MDSCs from late-stage melanoma patients 
(CD14posHLA-DRlowCD33posCD11bpos) cultured with (A) vehicle control (DMSO) and 


































5.2 PFKFB3 inhibition reduces A375-MDSC suppressive activity 
We next sought to recapitulate the findings of PFKFB3 inhibition in 
circulating M-MDSCs from late-stage melanoma patients using MDSCs derived 
from the A375:monocyte co-culture model. We tested two independent models 
for different timing of PFKFB3 inhibition by PFK-158. In the first model, we 
cultured A375 melanoma cells with CD14pos monocytes from normal donors in 
the presence of PFK-158 during the induction phase, followed by co-culturing 
purified A375-MDSCs (CD14posCD11bpos) with CFSE labeled autologous T cells 
for an additional 96 hours (Fig. 54). In the second model, A375:monocyte co-
culture was allowed to differentiate for 72 hours, followed by purification of A375-
MDSCs which were then treated with PFK-158 and vehicle control for 16-18 
hours and then co-cultured with CFSE labeled autologous T cells for four days 
(Fig. 55). At the end of the 96-hour MDSC:T cell co-culture, T cell proliferation 
was measured by flow cytometry. In both the models, PFKFB3 inhibition resulted 
in reduced A375-MDSC suppressive activity as determined by increased T cell 
proliferation and IFN-γ production in PFK-158 treated A375-MDSC:T cell co-
cultures (Fig. 56 and 57). In the first model, PFK-158 was added during the 
CD14pos monocyte and A375 co-culture. This may have inadvertently resulted in 
reduced TDSFs from the decrease in melanoma cell line proliferation. In order to 
overcome this limitation, second model was employed where PFK-158 was 
added following CD11bpos cell sorting. On western blot analysis, A375-MDSCs 
expressed high PFKFB3 compared to cultured monocytes and fresh monocytes 
from normal donors (Fig. 58).  
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Next step was to determine the mechanisms for A375-MDSC suppressive 
activity. qRT-PCR showed that A375-MDSCs had high expression of both 
arginase 1 and iNOS mRNA compared with cultured monocytes (Fig. 59A and 
60A). PFKFB3 inhibition with PFK-158 resulted in significant decrease in mRNA 
expression of both these markers (Fig. 59B and 60B). Arginase assay showed 
that A375-MDSCs had significantly higher activity compared with fresh and 
cultured monocytes (Fig. 59C). The arginase activity decreased significantly 
following PFKFB3 inhibition (Fig. 59C). Furthermore, there was no difference in 
DCF-detectable ROS in A375-MDSC following PFKFB3 inhibition. These data 
validate our murine studies, where PFKFB3 inhibition was associated with 
reduced M-MDSC suppressive activity which correlated with significant 













Figure 54. Schematic representation of the steps involved in generation of 
A375-MDSCs and PFKFB3 inhibition during the differentiation process. 
CD14pos monocytes sorted from the peripheral blood of normal donor were 
cultured with A375 melanoma cells for four days. PFK-158 (5 µM) or vehicle 
control (DMSO) was added on day zero and day two. On day three, using 
magnetic bead separation CD11bpos cells were isolated as per manufacturer’s 
protocol. A375-MDSCs (CD14posCD11bpos) cells were then co-cultured with 
CFSE labelled autologous T cells for 96 hours and flow cytometry was performed 










Figure 55. Schematic representation of the steps involved in generation of 
A375-MDSCs and PFKFB3 inhibition post-differentiation process. CD14pos 
monocytes sorted from the peripheral blood of normal donor were cultured with 
A375 melanoma cells for three days. On day three, using magnetic bead 
separation CD11bpos cells were isolated as per manufacturer’s protocol. A375-
MDSCs (CD14posCD11bpos) were then treated with vehicle control and PFK-158 
(2.5 µM or 5 µM) for 16-18 hours. The following day, cells were washed and co-
cultured with CFSE labelled autologous T cells for 96 hours. Flow cytometry was 











Figure 56. PFKFB3 inhibition during the A375-MDSC differentiation process 
reduces their suppressive activity. Autologous CFSE-labeled T cells were 
cultured in the presence of fresh healthy donor monocytes (fresh mono), with 
monocytes cultured for 72 hours in the absence of melanoma cells (cultured 
mono), or with monocytes co-cultured with A375 cells in the absence (A375-
MDSC), or presence of PFK-158 (A375-MDSC + PFK-158 (5 µM), day zero and 
day two). T cells were activated with anti-CD3/anti-CD28 beads in the absence or 
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presence of the indicated monocytes/MDSCs for four days. (A) Representative 
histograms and (B) bar graphs showing the percentage of proliferated CFSE-
labeled T cells and (C) IFN-γ production. Results are representative of three 



















Figure 57. PFKFB3 inhibition in A375-MDSCs after differentiation reduces 
their suppressive activity. Autologous CFSE-labeled T cells were cultured in 
the presence of A375-MDSC treated with vehicle control and PFK-158 (2.5 µM or 
5 µM). T cells were activated with anti-CD3/anti-CD28 beads in the absence or 
presence of the indicated MDSCs for four days. Representative (A) histograms 
and (B) bar graphs showing the percentage of proliferated CFSE-labeled T cells 
and (C) IFN-γ production. Results are representative of three independent 







Figure 58. PFKFB3 is over-expressed in A375-MDSCs. Western blot analysis 
of PFKFB3 expression in A375-MDSCs compared with fresh and cultured 
monocytes. (A) Western blot film and (B) bar graphs showing relative PFKFB3 
expression in fresh monocytes, cultured monocytes and A375-MDSCs. Results 
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Figure 59. PFKFB3 maintains arginase expression in A375-MDSCs. Bar 
graphs showing results of (A) qRT-PCR of arginase 1 mRNA expression in 
healthy donor monocytes (n=5) cultured for 72 hours in the absence (cultured 
monocytes) or presence of A375 cells, (B) qRT-PCR of arginase 1 mRNA 
expression in A375-MDSCs treated with vehicle control and PFK-158 and (C) 
QuantichromTM arginase assay showing arginase activity in cell lysates from 
fresh monocytes, cultured monocytes, A375-MDSC treated with vehicle control 
and PFK-158. Results are representative of three independent experiments. 
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Figure 60. PFKFB3 maintains iNOS mRNA expression in A375-MDSCs. Bar 
graphs showing results of (A) qRT-PCR of iNOS mRNA expression in healthy 
donor monocytes (n=5) cultured for 72 hours in the absence (cultured 
monocytes) or presence of A375 cells, (B) qRT-PCR of iNOS mRNA expression 
in A375-MDSCs treated with vehicle control and PFK-158, and (C) histogram of 
mean fluorescent intensities (MFI) of DCF-detectable ROS in A375-MDSC 
treated with vehicle control and PFK-158. Results are representative of three 










5.3 A375-MDSCs upregulate glycolysis and lactic acid production 
We have shown that A375-MDSCs over express PFKFB3 which is 
associated with high rate of glycolysis. We used the Seahorse® platform to study 
the bioenergetic profile of A375-MDSCs. Using the Seahorse® platform, ECAR 
and OCR for fresh monocytes from healthy donor, cultured monocytes 
(monocytes cultured for 72 hours in the absence of A375 cells) and A375-
MDSCs was measured. A375-MDSCs had significantly higher ECAR compared 
with fresh and cultured monocytes indicating high rate of glycolysis in these cells 
(Fig. 61A). A375-MDSCs also had higher OCR compared to the fresh and 
cultured monocytes (Fig. 61B). Next, we sought to determine is PFKFB3 
inhibition resulted in decrease in the rate of glycolysis. A375-MDSCs were 
treated with vehicle control and PFK-158 (5 µM) for 16-18 hours. The following 
day, cells were washed and plated in the Seahorse® XFe96 plate. ECAR and 
OCR were measured. PFKFB3 inhibition with PFK-158 resulted in significant 
decrease in both ECAR and OCR compared to treatment with vehicle control 
(Fig. 61C and D).   
 Increased rate of glycolysis as a consequence of over-expression of 
PFKFB3 is associated with increased production of lactic acid. Increased lactic 
acid in addition to the upregulation of arginase and iNOS likely provides MDSCs 
with an additional mechanism for suppression of T cell activity. Lactate assay 
showed that A375-MDSCs produced increased amount of lactic acid compared 
to cultured monocytes which decreased following PFKFB3 inhibition with PFK-
158 (Fig. 62A). In addition, we also assessed change in lactic acid production by 
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circulating M-MDSCs from late-stage melanoma patients following PFKFB3 
inhibition. Similar results were obtained where lactic acid production decreased 
significantly following overnight treatment with PFK-158 (5 µM) (Fig. 62B). In line 
with its mechanism of action, treatment with PFK-158 decreased the intracellular 








Figure 61. PFKFB3 over-expression maintains high rate of glycolysis in 
A375-MDSCs. Bioenergetic analysis was performed using the Seahorse® 
platform to determine extracellular acidification rate (ECAR) and oxygen 
consumption rate (OCR) in fresh monocytes, cultured monocytes and A375-
MDSCs and A375-MDSC + PFK-158. Representative bar graphs showing results 
of (A) ECAR and (B) OCR of fresh monocytes, cultured monocytes and A375-
MDSCs. Representative bar graphs showing results of (C) ECAR and (D) OCR 
of A375-MDSCs treated with vehicle control and PFK-158. Results are 
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Figure 62. PFKFB3 inhibition reduces lactic acid production and 
intracellular concentration of F-2,6-BP. Lactate assay was performed using 
the supernatants from cultured monocytes, A375-MDSCs + vehicle control and 
A375-MDSCs + PFK-158 (5 µM). Peripheral blood M-MDSCs from late-stage 
melanoma patients were cultured with vehicle control or PFK-158 (5 µM) for 16-
18 hours and supernatant was collected for lactic acid production. 
Representative bar graphs showing results of lactic acid measurements for (A) 
cultured monocytes, A375-MDSCs + vehicle control and A375-MDSCs + PFK-
158, and (B) circulating M-MDSCs treated with vehicle control and PFK-158. (C) 
A375-MDSCs were treated with vehicle control or PFK-158 post-differentiation 
for 16-18 hours and intracellular concentration of F-2,6-BP was determined 
based on previously described protocol (88). Results are representative of three 
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5.4 Treatment of cancer patients with PFK-158 reduced the frequency of 
circulating M-MDSCs and increased activated T cells 
To study the effects of PFKFB3 inhibition on the immune cell populations 
in human patients, we analyzed the peripheral blood from a patient with 
metastatic breast cancer who had responded to treatment on a Phase 1 clinical 
trial with PFK-158. At cycle one day one (C1D1), patient had high circulating M-
MDSCs (LinnegCD14posCd11bposHLA-DRlow) (Fig. 63A). However, at C1D22 of 
PFK-158 administration the percentage of the circulating M-MDSCs decreased 
by over six fold (Fig. 63B). The decrease in the frequency of M-MDSCs was 
associated with not only a decrease in the frequency of other immune 
suppressive populations but also an increase in the percentage of activated CD8 
T cells (Fig. 64 A-C). Imaging studies showed that the same patient had 
stabilization of vertebral bony mets and necrosis of liver lesions following four 




Figure 63. PFK-158 treatment was associated with a decrease in the 
circulating M-MDSCs in a patient with metastatic breast cancer. Flow 
cytometry analysis of peripheral blood in a patient with metastatic breast cancer 
who had responded to the treatment on Phase 1 clinical trial with PFK-158. 
Representative contour plots at (A) cycle one day one (C1D1) and (B) C1D22 of 
PFK-158 treatment showing percentage of LinnegCD14posCD11bposHLA-DRlow M-




Figure 64. PFK-158 treatment was associated with a decrease in the 
percentage of immune suppressive and an increase in the activated CD8 T 
cell populations. Representative line graph showing the trend of (A) immune 
suppressive and (B) activated T cell populations following each cycle of PFK-
158, cycles one through 22 in a patient with metastatic breast cancer. (C) 
Percentage change (expressed as mean ± SD) in the immune cellular population 









Figure 65. Patient with metastatic breast cancer who received PFK-158 as 
part of Phase study had stabilization of vertebral bony mets and necrosis of liver 








6.0 DISCUSSION, CONCLUSION AND FUTURE DIRECTIONS 
 
6.1 Discussion and Conclusion: 
Complex interactions between the tumors and the immune system have 
recently received tremendous attention. The concept of “cancer immune 
surveillance” or recently rephrased as “cancer immunoediting” was first described 
more than a century ago (89, 90). This concept is divided in to three phases – 
elimination, equilibrium and escape (89, 90). In the elimination phase, the 
immune system is able to recognize and eliminate the cancer cells. Partial 
elimination of the cancer cells can result in a state of equilibrium during which 
cancer cells continue to evolve and mount increasing pressure on the immune 
system, ultimately leading to the escape phase. During the escape phase, 
tumors not only evolve to express epitopes that are not recognized by the 
immune system but also secrete factors or ligands that attract immune 
suppressive populations and downregulate effective anti-tumor responses by the 
immune effector cells.  
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In 2011, recognizing the importance of immune system in cancer 
development and progression, Hanahan and Weinberg published an update to 
their original publication “The Hallmarks of Cancer” (91). This update included an 
emerging hallmark “avoiding immune destruction” and an enabling characteristic 
“tumor-promoting inflammation” (92). Experimental animal models have shown 
that deficiencies in the development or function of CD8 CTLs, CD4 Th1 or NK 
cells increase their susceptibility to tumor development (90, 93). Combined 
deficiencies in both T and NK cells further enhances the susceptibility to tumor 
development indicating the importance of both the innate and the adaptive 
immune system in immune surveillance and tumor eradication (90, 93). Similarly 
in transplantation models, cancer cells from immunodeficient mice are not 
capable of initiating tumors in syngeneic immunocompetent hosts; however, 
cancers cells from immunocompetent mice are able to initiate tumors in both 
immunodeficient and immunocompetent hosts (90). These models highlight the 
concept of highly immunogenic tumors which induce effective anti-tumor 
responses as opposed to weakly immunogenic tumors. Some highly 
immunogenic tumors include RCC, melanoma and merkel cell carcinoma where 
spontaneous regressions are not uncommonly seen. In addition, the induction of 
inflammatory response in the tumors and recruitment of immune suppressive 
inflammatory cells to the TME promote tumor growth and suppress anti-tumor 
immune responses.   
Better understanding of these complex interactions between the tumors 
and the immune system has helped us make significant advances in the field of 
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cancer immunotherapy. New therapies such as immune checkpoint blockade 
mAbs and adoptive cell therapies (ACT) have translated in to better response 
rates (RR) and OS in cancer patients. Presence of lymphocytic infiltrates within 
the tumor has been shown to correlate highly with improved outcomes across 
various tumor subtypes (94-97). These tumor infiltrating CD4 and CD8 T cells 
recognize TAAs and are tumoricidal as proven by the anti-tumor activity of 
adoptively transferred ex vivo expanded tumor-infiltrating lymphocytes (TILs). 
Further, the response to treatment strongly correlates with the absolute numbers 
of CD8 T cells infused. In phase III clinical trials, anti-CTLA4 monoclonal 
antibody ipilimumab showed a four month increase in median OS in patients with 
metastatic melanoma which has translated into long-term survival in 20–25% 
(98-100). More striking results were seen with anti-PD1/anti-PD-L1 blocking 
therapies with ORR ranging from 18 to 52% across different cancer types and 
well selected patients (101-103). In addition, these therapies are associated with 
durable complete remissions (CR) even after the discontinuation of the therapy. 
Despite these advances, many patients still fail to achieve any meaningful 
response.  
Resistance to immune checkpoint blockade therapies has been described 
at two levels – intrinsic and naturally acquired resistance (104). Patients who are 
non-responders, lack anti-tumor immune response and fail to elicit an effective T 
cell response upon immunotherapy are described to have intrinsic resistance 
(104). This could be the result of local or systemic factors that contribute to 
ineffective anti-tumor response. Systemic factors could be related to a weak 
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immune system especially in the elderly and immunodeficient patients or 
expression of few neoantigens by certain tumors. Local factors are associated 
with lack of TILs or tolerogenic TME. T cell function in the TME is inhibited by the 
infiltration of suppressive myeloid and lymphoid cells, expression of inhibitory 
receptors/ligands and secretion of inhibitory cytokines by the tumors and immune 
suppressive cells (Table. 4) (104). Naturally acquired resistance occurs when 
patients may have an ongoing anti-tumor immune response but fail to derive any 
benefit from immune modulatory therapies (104). This may result from 
loss/downregulation of MHC class I by tumor cells or from expression of other T 
cell inhibitory receptors (Table. 4).    
Numerous therapeutic strategies are currently under or in late-phase 
development which are designed to target the immune suppressive components 
of the TME. These include modalities to strengthen T cell responses by ex vivo 
enrichment of antigen-specific T cells, chimeric antigen receptor T cells and 
combination of immune checkpoint blockade agents such as ipilimumab and 
nivolumab. Inhibitors of immune suppressive molecules such as IDO 
(ClinicalTrials.gov Identifier: NCT02752074) are currently being studied in 
combination with immune checkpoint blockade antibodies. Combination 
therapeutic strategies with chemotherapy agents, radiotherapy and small 
molecule inhibitors with immune checkpoint blocking agents are being studied as 
they have been shown to modulate the TME by reducing immune suppressive 




Table 4. List of immune suppressive cells and negative regulators of T cell 
function (104, 105). 
Immune suppressive 
cells 




Regulatory T cells (Tregs) Programmed cell death 
protein 1 (PD1) 
Transforming growth 
factor-β 
T helper 17 cells (Th17) Cytotoxic T-lymphocyte-
associated protein 4 
(CTLA4) 
Interleukin-1 (IL-1), IL-6, 
IL-10, IL-12, IL-17, IL-18  
Tumor associated 
macrophages (TAMs) 





arginase, nitric oxide (NO), 
peroxynitrite (PNT), 








Tumor necrosis factor-α 
(TNF-α) 
Tumor-associated 
fibroblast and other 
stromal cells 
Lymphocyte activation 
gene 3 protein (LAG3) 
 
 
Tolerogenic dendritic cells 
(DC) 
Inducible T cell co-
stimulator (ICOS) 
 
Type 2 natural killer T cells 
(NKT cells)  




suppressor cells (MDSCs) 
CD28  
Regulatory B cells   
Regulatory γδ T cells   
 
MDSC targeting therapies are divided in to four major categories – 
deactivation of MDSCs, inducing differentiation of MDSCs to mature myeloid 
cells, inhibition of myeloid cell development in to MDSCs and depletion of 
MDSCs (30). Deactivation of MDSCs has been studied in the context of blocking 
the suppressive markers such as arginase 1, ROS and iNOS. COX-2 inhibitors 
have been shown to reduce the expression of arginase 1 (30). Agents like ATRA 
have been shown to induce the differentiation of MDSCs to mature myeloid cells 
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(30). Bisphosphonates block the differentiation of myeloid cells to MDSCs and 
chemotherapy agents such as 5-FU and gemcitabine, and recently, ibrutininb has 
been shown to deplete MDSCs (30). However, randomized controlled studies to 
study the effect of these therapeutic strategies on MDSC populations are lacking.  
Our studies demonstrate for the first time a correlation between 
upregulated glycolysis and immune suppressive phenotype of monocytic 
MDSCs. We show that the enzyme PFKFB3, an important regulator of glycolysis 
is over-expressed in M-MDSCs and is required for their functional differentiation. 
We had demonstrated previously that circulating M-MDSCs in late-stage 
melanoma patients are differentially expanded and result in T cell suppression 
(50). We now provide further evidence that in B16-F10 melanoma and BM-
MDSC model, monocytic and not polymorphonuclear MDSCs are suppressive to 
T cell function. In an attempt to evaluate the role of PFKFB3 in modulating the 
immune suppressive phenotype of M-MDSCs, we isolated CD14pos circulating M-
MDSCs from late-stage melanoma patients. Ex vivo inhibition of PFKFB3 with 
the first-in-class small molecule inhibitor, PFK-158 improved T cell activity and 
IFN-γ production. Similar results were seen in A375-MDSCs, an ex vivo model of 
human MDSCs. PFKFB3 inhibition in murine splenic M-MDSCs reduced antigen 
specific T cell suppression. In splenic M-MDSCs cultured under hypoxic 
conditions and bone marrow-derived M-MDSCs, PFKFB3 inhibition reduced the 
antigen non-specific T cell function. Interestingly, in vivo PFKFB3 inhibition both 
in mice and in patients enrolled under Phase 1 study resulted in substantial 
155 
 
decline in M-MDSC population. In mice, splenic M-MDSC suppressive activity 
was also reduced following treatment with PFK-158.   
 High rate of glycolysis and increased glucose catabolism has been well 
described in tumors (58, 59). Glycolysis alone is insufficient to meet the energy 
needs of the cell. However in addition to ATP, tumors also need biosynthetic 
precursors from glycolytic intermediates in order to proliferate and invade (32). 
Furthermore, high glycolytic flux to pyruvate/lactate decreases intracellular and 
extracellular pH causing apoptosis in the neighboring normal cells (18, 32, 58-
60). Tumors are able to upregulate glycolysis through over-expression of several 
key regulators of glycolysis including PFKFB3. This enzyme produces F-2,6-BP 
that allosterically activates PFK-1, an irreversible and committed step that 
dictates the pace of glycolysis.  
A previous study showed that mTORC1-dependent aerobic glycolysis was 
necessary for lineage differentiation of M-MDSCs but not PMN-MDSCs (72). 
And, exposure to GM-CSF and IL6 has been shown to upregulate L-glutamine 
and glucose metabolism by anaerobic glycolysis resulting in the accumulation of 
TCA or Kreb cycle intermediates, lactic acid, and upregulated production of 
energy-rich nucleotides, arginase and iNOS (69). Fumarate and succinate both 
TCA cycle intermediates and lactic acid have been shown to stabilize the 
expression of HIF-1α through inhibition of HIF hydroxylases resulting in 
upregulated PFKFB3 expression and glycolysis in M-MDSCs (24, 63, 85). In our 
study, we showed that HIF-1α maintains the expression of PFKFB3 in M-MDSCs 
especially under hypoxia. Yet, another study showed that monocytes exposed to 
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hypoxia rapidly stimulate glycolysis by activating PFKFB3 through 
phosphorylation of serine (58). However, PMN-MDSCs have been shown to 
upregulate FAO along with an increase in mitochondrial mass and oxygen 
consumption rate (53). These differences in metabolic profiles of PMN- and M-
MDSCs may explain functional differences in these two subsets. Despite, the 
well-established role of PFKFB3 in carcinogenesis, its role as an 
immunomodulator has never been explored. Similar to the tumors, our studies 
show that M-MDSCs over-express PFKFB3, upregulate glycolysis and produce 
lactic acid. And, PFKFB3 inhibition was associated with decrease in glycolysis 
and lactic acid production. These data suggest that increased rate of glycolysis 
through upregulation of PFKFB3 may be necessary to maintain the suppressive 
phenotype of M-MDSCs. 
M-MDSCs mount their suppression on T cell activity primarily through the 
increased expression of arginase 1 and iNOS (Fig. 66) (4, 12, 19, 34, 36, 42). L-
arginine is very important for T cell function and its depletion by arginase 1 and 
iNOS results in translational blockade of CD3ζ chain and prevents T cells from 
responding to various stimuli (10, 26, 38). In addition, iNOS catabolizes L-
arginine producing NO as a by-product that causes nitrosylation of the TCR (36, 
52). In our study, we confirmed that M-MDSCs express high levels of arginase 1 
and iNOS, and PFKFB3 inhibition with PFK-158 reduced the expression or 
activity of both these markers. However, we did not see any change in the 
expression of NOX2 or NOX 4 enzymes nor did we see a change in DCF-
detectable ROS. These findings fall in line with the functional and metabolic 
157 
 
changes reported in activated macrophages and DCs where inflammatory 
signals or hypoxia stimulate the upregulation of glycolysis, lactic acid production 
and flux through PPP, and decreased oxygen consumption (63, 65, 66). This is 
accompanied by increased expression of inflammatory genes such as iNOS and 
Arg1 (63, 67, 68). Furthermore, in macrophages it has been shown that lactic 
acid can stabilize HIF-1α even under normoxic conditions and stimulate the 
expression of Arg1 and VEGF (85). Hypoxia in macrophages can also induce 
iNOS-HRE which can activate iNOS promoter and mRNA expression (86). 
Similarly in BM-MDSCs, GM-CSF and IL6 result in increased L-glutamine and 
glucose metabolism by anaerobic metabolism, accumulation of lactic acid and 
increased expression of Arg1 and iNOS (69). In our present study, we do not 
provide any evidence for the mechanistic link between upregulated glycolysis in 
M-MDSCs and increased expression of Arg1 and iNOS. We speculate that 
similar mechanisms linking hypoxia and production of lactic acid with increased 
expression of Arg1 and iNOS may exist in M-MDSCs as have been described in 
activated macrophages. However, neutrophils also have been shown to 
upregulate glycolysis but have significant increase in oxygen consumption which 
is used primarily to produce ROS (62). Likely a similar mechanism is in play in 
PMN-MDSCs where increase in oxygen consumption and mitochondrial mass 
generates NAPDH required for production of ROS by NOX enzymes (Fig. 67). 
The ability to upregulate HIF-1α, PFKFB3 and anaerobic glycolysis provides M-
MDSCs with the ability to survive in the hypoxic TME and differentiate in to 
TAMs. PMN-MDSCs on the other hand increase the mitochondrial mass and 
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oxidative phosphorylation and produce ROS; but are unable to survive in hypoxic 
TME.  
Several observational studies have demonstrated the role of increased 
number of MDSCs – both polymorphonuclear and monocytic in downregulating T 
cell responses in cancer patients. This increase is also correlated with poor 
prognosis and OS (2, 10, 12, 13, 15, 17, 21, 50, 52). Our studies involving 
PFKFB3 inhibition in both murine and human M-MDSCs provide strong evidence 
for the role of PFKFB3 in maintaining M-MDSC induced T cell suppression. PFK-
158 is a first-in-class small molecule inhibitor of PFKFB3 developed in the lab of 
Jason Chesney at the University of Louisville. A phase 1 clinical trial was 
conducted at four major institutions in the United States. Patients with solid 
tumors who had failed at least one previous regimen were enrolled. Drug was 
dosed at 24 mg/m2 to 650 mg/m2 delivered intravenously every other day for 
three weeks followed by one week rest. Cycle was repeated every four weeks 
until disease progression or unacceptable toxicity. Out of 27 patients enrolled 
under the study, 18 patients completed two cycles. Six of the 18 patients 
experienced clinical benefit in terms of stable disease (SD) and no drug-related 
serious adverse effects (SAEs) were reported. In addition to the decrease in M-
MDSC population, patients with clinical benefit showed a decrease in Th17 and 
γδ regulatory T cells and an increase in CD4pos and CD8pos effector T cells. 
Following treatment, PD1 expression on CD8pos T cells decreased. Results from 




Based on the data presented in this study, there is strong evidence that 
PFKFB3 inhibition or downregulation of glycolysis modulates M-MDSC 
suppressive function while it has no impact on PMN-MDSC frequency or function 
(Fig. 66 and 67). We believe that PFKFB3 inhibition improves anti-tumor immune 
responses in vivo through reduction in the frequency and suppressive function of 
M-MDSCs (Fig. 66). Further, immunomodulatory effects of PFK-158 were seen 
primarily in the low-dose cohorts in the Phase 1 clinical trial which indicates that 
anti-tumor responses were primarily driven through the decrease in the 
frequency and downregulation of M-MDSC suppressive function, and increase in 
the activity of CD8pos T cells as opposed to entirely the anti-tumor activity of the 
drug. Although it would be reasonable to suspect that there was some anti-tumor 
activity which may have contributed to reduced tumor volumes and decrease in 
secretion of TDSFs resulting in decrease in the number of circulating M-MDSCs. 
However, anti-tumor effect of PFK-158 would not be as dramatic as seen in the 





Figure 66. Model for M-MDSC induced T cell suppression and reversal of 
suppression with PFK-158. 
 
Figure 67. Model for PMN-MDSC induced T cell suppression with no 
reversal seen with PFK-158. 
 We present here some very exciting results from our studies but we also 
realize few limitations and/or pitfalls. We used B16-F10 transplantation model to 
study the functional and metabolic characteristics of MDSCs. 
Subcutaneous/transplantation tumor models do not recapitulate natural history or 
progression of tumors in animals or humans. This in turn may not provide true 
161 
 
insights into patterns of accumulation of immune suppressive populations let 
alone their functional characteristics at primary site versus metastatic lesions 
versus in circulation. In order to overcome this limitation, use of the MT/ret 
transgenic mouse may prove to be a better model to study various immune 
suppressive populations including MDSCs. These mice express the human ret 
transgene in melanocytes which is controlled by the mouse metallothionein I 
promoter-enhancer and develop spontaneous malignant cutaneous melanoma 
which metastasizes to lymph nodes, lungs, brain, kidney, and spleen (106, 107). 
This model shows similarity to human melanoma with respect to histopathology 
and clinical development and provides ability to study natural interactions of 
tumors with the host immune system over a period of time (106, 107). Also for 
future in vivo tumor experiments, we may use a tumor cell line with knock-down 
expression of PFKFB3 so that the tumor growth and the secretion of TDSFs is 
not significantly different between the PFK-158 and vehicle-treated mice.          
 MDSCs are characterized by their morphological, phenotypic and 
functional heterogeneity. This exhibits their incredible plasticity and how different 
conditions – different cancers and infections can modulate this immune 
suppressive myeloid population (24). The heterogeneity of MDSCs is also 
exhibited in the fact that in some tumor models PMN-MDSCs and in others M-
MDSCs are suppressive (35). Many previous studies reported in the literature 
were limited by the ambiguous morphological and functional markers of PMN- 
and M-MDSCs, and hence, the results of these studies did not reflect upon the 
true characteristics of these cells. Furthermore, MDSCs in humans lack a true 
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homologue of GR1 as in mice or unique surface marker, thus impairing the ability 
to specifically target them with mAb. In order to overcome the ambiguity and 
confusion related characterization of MDSC subsets, consensus standards have 
been published (35). In our studies, we preferentially followed phenotypic and 
functional characteristics defined recently as per consensus standards. Despite 
adhering to current standards, we suspect that as our knowledge of this highly 
heterogeneous myeloid cellular population grows the results of our current study 
may need to be refined based on prevailing phenotypic and functional definitions.  
 In our study, we report that in mice in vivo experiments and in patients on 
Phase 1 clinical trial, a marked reduction in the circulating M-MDSC population 
was seen. However, in the in vitro experiments we report no change in cell 
viability. Justification for these disparate results lies in the fact that different 
doses of PFK-158 were used for in vitro and in vivo experiments. For the in vitro 
experiments, we used non-lethal dose of PFK-158 to demonstrate the 
immunomodulatory effects resulting from PFKFB3 inhibition and not from 
elimination of M-MDSCs. Also, M-MDSCs were normalized to number for these 
functional studies. For the in vivo mice experiments, previously studied dose of 
PFK-158 was used and for patients on Phase 1 clinical trial, maximal tolerated 
dose (MTD) for human subjects was being determined. The decrease in the M-
MDSC population in mice following subcutaneous injection and in human 
patients following parenteral injection is thought to be secondary to the higher 
dose and likely from decrease in the Th17 cells which regulate MDSCs. In order 
to overcome these limitations and to determine the direct effect of PFKFB3 
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inhibition on M-MDSC mediated T cell suppression, we plan to conduct tumor 
inoculation studies and ex vivo M-MDSC functional analysis in PFKFB3 
conditional knockout (KO) mice. We will compare tumor growth and ex-vivo 
function of splenic M-MDSCs from PFKFB3 KO mice with WT mice. A cross 
between PFKFB3flox/flox and lysM-Cre mice will help us determine the requirement 
of the PFKFB3 expression for suppressive function of the myeloid compartment 
when compared with tumor-bearing WT mice.  
 We also concede that other metabolic inhibitors that target glycolysis and 
glycolytic enzymes may have similar immunomodulatory effects on M-MDSCs as 
PFK-158. Furthermore in our current study, we do not show changes in the 
expression of HIF-1α if any following PFKFB3 inhibition as HIF-1α is thought to 
be the likely promoter of expression of inflammatory genes such as Arg1 and 
iNOS.     
In conclusion, we show that in the melanoma model, M- and not PMN-
MDSCs suppress T cell activity. M-MDSCs express high PFKFB3 resulting in 
high rate of glycolysis and lactic acid production. Increased PFKFB3 expression 
in M-MDSCs under hypoxic conditions is dependent on expression of HIF-1α and 
is required to maintain their suppressive phenotype, and expression of 
inflammatory genes such as Arg1 and iNOS. PFKFB3 inhibition was associated 
with reduced M-MDSC suppression and improved T cell activity and function in 
vitro. PFKFB3 inhibition in vivo was associated with reduced M-MDSC frequency 
and tumor volumes, and reduced suppressive activity. Metabolic targeting of this 
highly suppressive population with PFK-158 provides an opportunity to further 
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improve anti-tumor T cell responses especially in combination with immune 
checkpoint blockade.   
6.2 Future directions 
 These are exciting times in oncology, especially in cancer immunotherapy. 
Prior to the FDA approval of anti-CTLA4 antibody ipilimumab (Yervoy®) in March 
2011, immunotherapy in solid malignancies was mostly discredited. High-dose 
IL-2 in advanced melanoma and RCC was associated with significant toxicities 
and poor response rates. At present, numerous clinical trials with anti-PD1 alone 
or in combination with anti-CTLA4 or anti-TIM3 or anti-LAG3 mAbs are ongoing 
in different cancer types. Immunotherapies are also being studied in combination 
with contemporary cancer treatments such as chemo and radiotherapies. Despite 
ORR upwards of 20% across different cancer subtypes, intrinsic and naturally 
acquired resistance to anti-PD1 therapies are being recognized in non-
responders. Agents that target other immune checkpoint receptors or immune 
suppressive populations are now being studied to overcome this resistance. In 
our study and Phase 1 clinical trial with PFK-158, we provide substantial 
evidence for PFKFB3 inhibition as a novel immunomodulatory therapeutic agent. 
PFKFB3 inhibition decreases immune suppressive M-MDSC population and its 
suppressive activity and can be effectively combined with immune checkpoint 
blockade therapies for improved anti-tumor T cell responses. We next intend to 
study PFKFB3 inhibition in combination with anti-PD1/anti-CTLA4 therapy in the 
165 
 
context of a Phase 1 clinical trial and hopefully, bring this novel treatment 
strategy to the clinic and to the patients.  
 Further, our study has laid the foundation to study the metabolic profile of 
TAMs as they differentiate from M-MDSCs in the TME. We suspect that PFKFB3 
is over-expressed in TAMs and PFKFB3 inhibition with PFK-158 will modulate 
their immune suppressive profile, thus providing another mechanistic link to 
immunomodulatory effects of PFK-158. We have provided evidence that increase 
in the rate of glycolysis in M-MDSCs results in the upregulation of Arg1 and 
iNOS; however, exact mechanistic link between the two is still not clear. Future 
project can attempt to identify the link between upregulated glycolysis and 
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